1
Status: Approved ,Date: 19 September 2016Janssen Research & Development *
Clinical Protocol
A Phase 2, Randomized, Double- blind, Placebo -controlled Study  to Evaluate the 
Pharmacokinetics, Safety, and Antiviral Activity  of JNJ -63623872 in Combination With 
Oseltamivir in Adult and Elderly  Hospitalized Patients With I nfluenza A Infection
Protocol 63623872FLZ2002; Phase 2
AMENDMENT 3   
JNJ-63623872   
*Janssen Research & Development is a global organization that operates through different legal 
entities in various countries. Therefore, the legal entity  acting as the sponsor for Janssen 
Research & Development studies may  vary , such as, but not limited to Janssen Biotech, I nc.; 
Janssen Products, L P; Janssen Biologics, BV; Janssen -Cilag International NV; Janssen, I nc; 
Janssen Sciences Ireland UC; or Janssen Research & Development, LL C. The term “sponsor” is 
used throughout the protocol to represent these various legal entitie s; the sponsor is identified on 
the Contact Information page that accompanies the protocol.
This study  will be conducted under US Food & Drug Administration I NDregulations (21 CFR 
Part 312).
EudraCT NUMBER: 2015 -003002 -17
Status: Approved
Date: 19 September 2016
Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV
EDMS number : EDMS- ERI-106482090, 7.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice , and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and ma y 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to a ll future information supplied to you that is indicated as privileged or 
confidential.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
2
Approved , Date: 19 September 2016Protocol History
63623872FLZ2002
Document T ype and
File Name Issued DateAmendment
Type Comments
Initial Clinical Trial Protocol
63623872FLZ200 2_Protocol05-Aug-2015 - -
Protocol Amendment I
63623872FLZ200 2_Protocol_Amend_123-Oct-2015 SubstantialFor details, please refer to 
Section Amendm ent 1
Protocol Amendment II
63623872FLZ200 2_Protocol_Amend_209-Dec-2015 SubstantialFor details, please refer to 
Section Amendm ent 2
Protocol Amendment III
63623872FLZ200 2_Protocol_Amend_3This document SubstantialFor details, please refer to 
Amendment 3
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
3
Approved , Date: 19 September 2016TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 3
LIST OF A TTACHMENTS ............................................................................................................................ 5
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 10
TIME AND EVENTS SCHE DULE –DURING HOSPITA LIZA TION (UP TO DISCHA RGE) ..................... 17
TIME AND EVENTS SCHE DULE –AFTER DISCHA RGE FROM HOSPIT AL......................................... 19
ABBREVIA TIONS ...................................................................................................................................... 21
1. INTRODUCTION ................................................................................................................................ 23
1.1. Background .................................................................................................................................... 23
1.2. Oseltamivir ..................................................................................................................................... 29
1.3. Overall Rationale for the Study ...................................................................................................... 30
1.4. Benefits and Risks Management ................................................................................................... 31
1.4.1. Known Benefits of JNJ -63623872 .............................................................................................. 31
1.4.2. Potential Benefits of JNJ -63623872 ........................................................................................... 31
1.4.3. Known Risks of JNJ -63623872 .................................................................................................. 31
1.4.4. Potential Risks of J NJ-63623872 ............................................................................................... 32
1.4.5. Overall Benefit/Risk Assessment ............................................................................................... 32
2. OBJECTIVES A ND HYPOT HESIS ................................................................................................... 34
2.1. Objectives ...................................................................................................................................... 34
2.2. Hypothesis ..................................................................................................................................... 35
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .35
3.1. Overview of Study Design .............................................................................................................. 35
3.2. Study Design Rationale .................................................................................................................. 36
4. SUBJECT POPUL ATION.................................................................................................................. 38
4.1. Inclusion Criteria ............................................................................................................................ 38
4.2. Exclusion Criteria ........................................................................................................................... 39
4.3. Prohibitions and Restrictions ......................................................................................................... 41
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 42
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 43
7. TREA TMENT COMPLIA NCE ............................................................................................................ 43
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 44
9. STUDY EVA LUATIONS .................................................................................................................... 45
9.1. Study Procedures ........................................................................................................................... 45
9.1.1. Overview ..................................................................................................................................... 45
9.1.2. Screening Phase ........................................................................................................................ 45
9.1.3. Double -Blind Treatment Phase .................................................................................................. 46
9.1.4. Posttreatment Phase (Follow -Up).............................................................................................. 47
9.1.5. After discharge from the hospital ................................................................................................ 47
9.2. Pharmacokinetics ........................................................................................................................... 48
9.2.1. Evaluations ................................................................................................................................ .48
9.2.2. Analytical Procedures ................................................................................................................. 49
9.2.3. Pharmacokinetic Parameters ..................................................................................................... 49
9.2.4. Pharmacokinetic Endpoints ........................................................................................................ 49
9.2.5. Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Evaluations .................................... 49
9.3. Safety Evaluations ......................................................................................................................... 49
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
4
Approved , Date: 19 September 20169.3.1. Adverse Events ........................................................................................................................... 50
9.3.2. Clinical Laboratory Tests ............................................................................................................ 50
9.3.3. Electrocardiogram ....................................................................................................................... 52
9.3.4. Vital Signs (temperature, pulse/heart rate, respirator y rate, blood pressure, blood 
oxygen saturation, level of consciousness) ................................................................................ 52
9.3.5. Physical Examination .................................................................................................................. 53
9.3.6. Specific Toxicities ....................................................................................................................... 53
9.4. Efficacy ........................................................................................................................................... 55
9.4.1. Evaluations ................................................................................................................................ .55
9.4.1.1. Patient- reported Outcomes ..................................................................................................... 55
9.4.1.2. Viral Kinetics (Nasal MT Swabs) ............................................................................................. 56
9.4.2. Efficacy  Endpoints ...................................................................................................................... 57
9.5. Resistance Evaluations .................................................................................................................. 57
9.5.1.1. Viral Sequencing ..................................................................................................................... 57
9.5.1.2. Phenotyping ............................................................................................................................. 57
9.6. Biom arkers ..................................................................................................................................... 57
9.7. Sample Collection and Handling .................................................................................................... 57
10. SUBJECT COMPLETION/W ITHDRA WAL....................................................................................... 58
10.1. Completion ..................................................................................................................................... 58
10.2. Discontinuation of Study Treatment ............................................................................................... 58
10.3. Withdrawal From the Study ............................................................................................................ 58
11. STATISTICA L METHODS ................................................................................................................. 59
11.1. Subject Information ........................................................................................................................ 59
11.2. Sample Size Determination ........................................................................................................... 59
11.3. Pharmacokinetic Analy ses............................................................................................................. 62
11.4. Pharmacokinetic/Pharmacodynamic Analyses .............................................................................. 64
11.5. Safety Analyses ............................................................................................................................. 64
11.6. Efficacy  Analyses ........................................................................................................................... 66
11.7. Biom arker Analyses ....................................................................................................................... 69
11.8. Data Monitoring Committee ........................................................................................................... 69
12. ADVERSE EVENT REPORT ING...................................................................................................... 69
12.1. Definitions ...................................................................................................................................... 69
12.1.1. Adverse Event Definitions and Classifications ........................................................................... 69
12.1.2. Attribution Definitions .................................................................................................................. 71
12.1.3. Severity Criteria .......................................................................................................................... 71
12.2. Special Reporting Situations .......................................................................................................... 71
12.3. Procedures ..................................................................................................................................... 72
12.3.1. All Adverse Events ...................................................................................................................... 72
12.3.2. Serious Adverse Events ............................................................................................................. 73
12.3.3. Pregnancy ................................................................................................................................... 74
12.4. Contacting Sponsor Regarding Safety ........................................................................................... 74
13. PRODUCT QUA LITY COMP LAINT HA NDLING .............................................................................. 74
13.1. Procedures ..................................................................................................................................... 74
13.2. Contacting Sponsor Regarding Product Quality ............................................................................ 75
14. STUDY DRUG INFORM ATION......................................................................................................... 75
14.1. Physical Description of Study Drug(s) ........................................................................................... 75
14.2. Packaging ...................................................................................................................................... 75
14.3. Labeling .......................................................................................................................................... 75
14.4. Preparation, Handling, and Storage ............................................................................................... 75
14.5. Drug Accountability ........................................................................................................................ 76
15. STUDY -SPECIFIC M ATERIA LS....................................................................................................... 76
16. ETHICA L ASPECTS ......................................................................................................................... 77
16.1. Study-Specific Design Considerations ........................................................................................... 77
16.2. Regulatory Ethics Compliance ....................................................................................................... 77
16.2.1. Investigator Responsibilities ....................................................................................................... 77
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................... 77
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
5
Approved , Date: 19 September 201616.2.3. Informed Consent ....................................................................................................................... 79
16.2.4. Privacy of Personal Data ............................................................................................................ 79
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 80
16.2.6. Countr y Selection ....................................................................................................................... 80
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 81
17.1. Protocol Amendments .................................................................................................................... 81
17.2. Regulatory Documentation ............................................................................................................ 81
17.2.1. Regulatory Approval/Notification ................................................................................................ 81
17.2.2. Required Prestudy Documentation ............................................................................................. 81
17.3. Subject Identification, Enrollment, and Scree ning Logs ................................................................ 82
17.4. Source Documentation ................................................................................................................... 82
17.5. Case Report Form Co mpletion ...................................................................................................... 83
17.6. Data Quality Assurance/Quality Control ........................................................................................ 84
17.7. Record Retention ........................................................................................................................... 84
17.8. Monitoring ...................................................................................................................................... 85
17.9. Study Com pletion/Termination ....................................................................................................... 86
17.9.1. Study Com pletion ....................................................................................................................... 86
17.9.2. Study Termination ....................................................................................................................... 86
17.10. On-Site Audits ................................................................................................................................ 86
17.11. Use of Information and Publication ................................................................................................ 86
REFERENCES ............................................................................................................................................ 89
ATTACHMENTS ......................................................................................................................................... 90
INVESTIGA TOR A GREEME NT............................................................................................................... 104
LAST PA GE.............................................................................................................................................. 104
LIST OF A TTACHMENTS
Attachment 1: WHO Toxicity  Grading Scale for Determining the Severity of Adverse 
Events (Feb 2003) .................................................................................................................... 90
Attachment 2: Anticipated Events ......................................................................................................... 95
Attachment 3 : Influenza Intensity and Impact Questionnaire (Flu -iiQTM).............................................. 96
Attachment 4: Additiona l Daily Diary Items to Flu -iiQTM........................................................................ 98
Attachment 5 : Flu-PRO Questionnaire .................................................................................................. 99
Attachment 6 : Additional Daily Diary Items to Flu- PRO ...................................................................... 101
Attachment 7: Cardiovascular Safety -Abnormalities ......................................................................... 103
LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Selected Single Dose JNJ -63623872 Pharmacokinetic Parameters ....................................... 26
Table 2: Variability for Key Pharmacokinetic Parameters for JNJ -63623 872 600 mg bid 
(Between -subjects %CV) .......................................................................................................... 60
Table 3: Precision of the LOESS Confidence Band Around the Prediction ........................................... 61
Table 4: Upper Confidence Limits for any Event with a Zero Incidence ................................................. 61
Table 5: Risk Differences and Associated 95% Confidence Intervals for Potential 
Treatment -emergent Adverse Event Incidences ...................................................................... 62
Table 6: Resolution Criteria for Vital Signs ............................................................................................. 66
Table 7: Ordinal Scale on Day 8 ............................................................................................................. 67
FIGURES
Figure 1: Example of LOESS Regression for a Simulated Data Set for C min(N=50) .............................. 61
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
6
Approved , Date: 19 September 2016PROTOCOL A MENDMENTS
Amendment 3 (This document)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment:
Inconsistencies , corrections, and other edits within the protocol.
Rationale: Based on the conflict between Exclusion Criterion 8 and Section 10.2, Exclusion Criterion 8 was 
adapted to not allow  subjects with chronic hepa titis C on treatm ent to enroll in the trial and the discontinuation 
criterion for hepatitis was removed from  Section 10.2. In view  of that, the discontinuation rules in Section 9.3.6
and Exclusion Criterion 7 were modified.
4.2Exclusion Criteria
9.3.6 Specific Toxicities
10.2 Discontinuation of Study Treatment
Rationale: Toxicity management was updated to accommodate more sev erely ill patients in the hospital setting.
9.3.6 Specific Toxicities
Rationale: Asecond 300-mg tablet formulation containing the equivalent of JNJ-63623872 free base has been 
developed by the Sponsor . The formulation information wasadded to Section 14.1.
14.1 Physical Description of Study Drug(s)
Rationale: Exclusion Criterion 3was modified to exclude severely immunocompromised subjects based on
CD4+and absolute neutrophil counts. The discontinuation criterion for absolute neutrophil count wasmodified
in Se ction 9.3.6.
SYNOPSIS
4.2Exclusion Criteria
9.3.6 Specific Toxicities
Rationale: Based on FDA feedback, swabbing for local virology testing was adapted to be done from both 
nostrils instead ofone (if feasible) .
TIME AND EVENTS SCHEDULE –During Hospitalization (Up to discharge)
TIME AND EVENTS SCHEDULE –After discharge From Hospital
9.1.2 Screening Phase
9.4.1.2 Viral Kinetics ( Nasal MT Swabs)
Rationale: Based on investigator feedback, timing of second dose was allowed to be brought forward with a 
maximum of 4hours from scheduled dosing (previously protocol language only allowed for movement of 
dosing back 4 hours ).
6DOSAGE AND ADMINISTRATION
Rationale: Based on investigator feedback, a footnote was added to the Time and Events Schedule to allow a 
historical ECG (prior to ICF sign -off)to be used for scre ening/baseline, with a window of 1 day . 
TIME AND EVENTS SCHEDULE –During Hospitalization (Up to discharge)
9.1.2 Screening Phase
9.3.3 Electrocardiogram
Rationale: Section 4.3 wasupdated following recent results ofthe oral contraceptive Phase 1 study (Study 
63623872FLZ1009) , which demonstrated no significant drug interaction between JNJ-63623872 and estrogen -
and progesterone -based oral contraceptives.
1.1Background
4.3Prohibitions and Restrictions
Rationale: Based on results of the 14C-AD ME study (Study 63623872 FLZ1007 ),there is little (~5%) 
CYP3A -mediated metabolism in vivo and therefore strong inhibitors or inducers of CYP3A metabolism were
removed from the list of disallow ed concomitant therapies.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
7
Approved , Date: 19 September 2016Amendment 2 (09 December 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment:
FDA feedback regarding (1) addition of a follow -up pregnancy test during treatment if pregnancy is a criterion 
for discontinuation of study drug and (2) addition of a hierarchal ordinal scale for clinical outcom e as a 
secondary efficacy endpoint.8PRESTUDY AND CONCOMITANT THERAPY
Rationale: Clarification to Exclusion Criterion 12 .
4.2Exclusion Criteria
Rationale: Clarification todose administration of oseltamivir based on the eGFR value.
SYNOPSIS
3.1Overview  of Study Design
6DOSAGE AND ADMINISTRATION
9.1.3 Double -Blind Treatment Phase
Rationale: Clarifications and minor additions to Section s 11.5 and 11.6.
11.5 Safety Analyses
11.6 Efficacy Analyses
Rationale: Minor edits to below  sections .
Front page
TIME AND EVENTS SCHEDULE –During Hospitalization (Up to discharge)
1.3Overall Rationale for the Study
3.1Overview  of Study Design
3.2Study Design Rationale
14.2 Packaging
Rationale: Based on feedback by the FDA, aurine pregnancy test (for females of childbearing potential) was 
added to Day 5 procedures .
TIME AND EVENTS SCHEDULE
9.1.3 Double -Blind Treatment Phase
9.3.2 Clinical Laboratory Tests
Rationale: Based on feedback by the FDA, a hierarchal ordinal scale for clinical outcome was added as a 
secondary efficacy endpoint.
SYNOPSIS
2.1Objectives
11.6 Efficacy Analyses
Based on feedback by the FDA , standard -of-care was added as additional therapy to hospitalized patients 
outside this protocol (at the investigator's discretion) .
9.1.3 Double -Blind Treatment Phase
Rationale: Based on recommendations related to contraception and pregn ancy testing in clinical trials published 
by the Clinical Trial Facilitation Group, th e double -barrier method of contraception was removed.
4.3Prohibitions and Restrictions
Rationale: Based on practical considerations ,sparse PK sam pling was adjusted for Day 2 and Days 4-7to: "On 
Day 2  and Days 4-7: predose (≤1 hour prior to dosing ) and betw een 1.5 and 6 hours after the morning or 
evening dose (whichever is the most convenient). "
TIME AND EVENTS SCHEDULE
9.2.1 Evaluations
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
8
Approved , Date: 19 September 2016Amendment 1 (23 October 2015 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: TheFDA didnot agree with the enrollment of adolescents because of 
insufficient Phase 2 safety and efficacy data in adults to support dosing in a pediatric population (Request for 
Additional Information 08 October 2015 ).Rationale: Based on practical considerations and to align with the current Investigator Brochure (no food 
effect) ,the requirement of dosing with food w as rem oved.
SYNOPSIS
3.1Overview  of Study Design
6DOSAGE AND ADMINISTRATION
9.2.1 Evaluations
Rationale: Level of consciousness was added to the vital sign measurement .The level of consciousness will be 
measured according to the AVPU scale (alert, voice, pain, unresponsive). The National Early Warning Score 
(NEWS) w ill be derived based on vital signs and AVPU scale at baseline and during hospitalization.
TIME AND EVENTS SCHEDULE
9.1.2 Screening Phase
9.3.4 Vital Signs (temperature, pulse/heart rate, respiratory rate, blood pressure , blood oxygen saturation , level 
of consciousness )
11.5 Safety Analyses
REFERENCES
Rationale: Based on practical considerations, the l imitation on regional r ecruitment was removed .
SYNOPSIS
3.1Overview  of Study Design
11.2 Sample Size Determination
Rationale: Minor edits w ere noted.
SYNOPSIS
TIME AND EVENTS SCHEDULE
ABBREVIATIONS
4.1Inclusion Criteria
5TREATMENT ALLOCATION AND BLINDING
9.2.1 Evaluations
9.2.2 Analytical Procedures
9.3.6 Specific Toxicities
12.1.1 Adverse Event Definitions and Classifications
12.3.1 All Adverse Events
14.1 Physical Description of Study Drug(s)
Attachment 2
Attachment 7
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
9
Approved , Date: 19 September 2016Rationale: Based on the request by the FDA ,all text regarding inclusion of the adolescent population was 
removed. Accordingly, the sample size justification was re -written.
SYNOPSIS
TIME AND EVENTS SCHEDULE
1.2Oseltamivir
1.3Overall Rationale for the Study
2.1Objectives
3.1Overview  of Study Design
4SUBJECT POPULATION
4.1Inclusion Criteria
4.3Prohibitions and Restrictions
9.1.2 Screening Phase
9.3Safety Evaluations
11.2 Sample Size Determination
11.3 Pharmacokinetic Analyses
12.1.1Adverse Event Definitions and Classifications
12.3.1 All Adverse Events
12.3.2 Serious Adverse Events
15STUDY -SPECIFIC MATERIALS
16.1 Study -Specific Design Considerations
16.2.2 Independent Ethics Co mmittee or Institutional Review Board
16.2.3 Informed Consent
17.2.2 Required Prestudy Documentation
Rationale: Re-wording was done to clarif yexclusion criterion #3 .
SYNOPSIS
4.2Exclusion Criteria
Rationale: Minor errors w ere noted.
TIME AND EVENTS SCHEDULE
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
10
Approved , Date: 19 September 2016SYNOPSIS
A Phase 2, Randomized, Double- blind, Placebo -controlled Study to Evaluate the Pharmacokinetics, 
Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and 
Elderly Hospitalized Patients With Influenza A Infection
JNJ-63623872 ( previously known as VX-787) is a non-nucleo tideinhibitor of the influenza A virus 
polymerase and is currently in Phase 2 development as treatment for influenza A infection.
Oseltamivir is an influenza neuraminidase inhibitor indicated for the treatment of acute, 
uncomplicated influenza in patients 2 weeks of age and older who have been symptomatic for no 
more than 2 days and for prophylaxis of influenza in patients 1 year and older.
OBJECTIVE SAND HYPOTHESIS
Primary Objective
The primary objective is to evaluate the pharmacokinetic (PK)parameters of JNJ-63623872 in 
combination with oseltamivir in elder ly subjects (aged 65 to ≤85years) compared to adults (aged 
18to ≤64 years )with influenza A infection.
Secondary Objectives
Secondary objectives include the assessment of the following parameters in the JNJ-63623872 
treatment arm compared to the control arm:
1. Safety and tolerability.
2. The time to influenza viral negativity based on quantitative reverse transcription polymerase 
chain reaction (qRT-PCR ) and/or viral culture from nasal mid-turbinate (MT) swabs and, if 
applicable, based on PCR -based rapid molecular testing from nasal MT swabs.
3. Viral load over time andrate of decline in viral load during treatment as measured by qRT-PCR 
and/orby viral culture.
4. Area under the curve (AUC) of viral load as measured by qRT -PCR and /orby viral culture.
5. Disease status and incidence of complications associated with influenza after the start of study 
treatment , and disease progression :
 bacterial pneumonia (cul ture confirmed where possible),
 other bacterial superinfections,
 respiratory failure,
 pulmonary disease (eg, asthma, chronic obstructive pulmonary disease [COPD]), 
 cardiovascular and cerebrovascular disease (eg, myocardial infarction, congestive heart 
failure [CHF], arrhythmia, stroke).
6. Change in duration and severity of clinical symptoms as measured by the Flu -PRO .
7. Time to improvement of vital signs.
8. Time to improv ement of respiratory status. 
9. Improvement on the ordinal scale.
10. Emergence of drug resistance as detected by genotype or phenotype.
11. Time to return to premorbid functional status.
12. Time to hospital discharge.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
11
Approved , Date: 19 September 2016Exploratory Objectives
Exploratory objectives include the assessment of the following parameters in the JNJ-63623872 
treatment arm compared to the control arm:
1. Use of antibiotics and/or corticosteroids during hospitalization.
2. Number of subjects admitted t o the Intensive Care Unit (ICU).
3. Length of ICU stay for subjects transferred to the ICU after baseline.
4. Correlation between the decline in viral load (measured by qRT-PCR and/or viral culture) and 
changes in clinical symptoms .
5. PK/pharmacodynamic (PD) relationship (efficacy and safety).
Hypothesis
No formal hypothesis will be tested.
OVERVIEW OF STUDY DESIGN
This is a randomized, double -blind, placebo -controlled, multicenter Phase 2 study to evaluate the 
effect of JNJ-63623872 600 mg twice daily (bid) versus (vs.) placebo, both in combination with 
oselta mivir 75mg bid in adult and elderly hospitalized subjects with influenza A infection. Up to 
90subjects in total will be enrolled in this study. An effort will be made to enroll aminimum of 
approximately 24subjects per age cohort.
Subjects who meet all eligibility criteria will be randomized in a 2:1 ratio to receive 1 of the following 
2treatments:
 JNJ-63623872 600 mg bid + oseltamivir 75 mg bid; OR
 JNJ-63623872 placebo bid + oseltamivir 75 mg bid
All st udy drug swillbe taken orally .
The study will consist of a screening/ baseline visit, a double -blind treatment period of 7days, and 
afollow -up period of 21 days.
The entire study duration for each subject will be 28days with study assessments daily during the 
treatment period, and on Days 10, 14, and 28 of the follow -up period. The study is considered 
complete with the completion of the last study assessment for the last subject participating in the 
study.
SUBJECT POPULATION
In order to start treatment as soon as possible after the start of the influen za infection, screening will 
occur on Day 1, before randomization and the first administration of study drug.
Key Inclusion Criteria
 Subject requires hospitalization to treat influenza infection and/or to treat complications of 
influenza infection.
 Subject tested positive for influenza A infection within 1 dayof signing of the informed consent 
form (ICF) using a PCR -based rapid molecular diagnostic assay .
 Subjects must be capable of swallowing study medication tablets and capsules.
 Male or female subject, 18 to 85 years of age (extremes included). 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
12
Approved , Date: 19 September 2016Key Exclusion Criteria
 Subject received more than 3 doses of the influenza antiviral medication oseltamivir, zanamivir, 
or peramivir since the start of the influenza symptoms, or ribavirin within 6 months prior to
screening.
 Subject is unwilling to undergo regular nasal MT swab sor has any physical abnormality which 
limits the ability to collect regular nasal specimens.
 Subject i s known (considering lab results of the past 6 months) to be severely 
immunocompromised as defined by a CD4+ count <350 cells/mm3 or anabsolute neutrop hil 
count < 750/mm3.
 Subject is undergoing peritoneal dialysis, hemodialysis ,or hemofiltration.
 Subject has an estimated glomerular filtration rate (eGFR ) ≤30 mL/min /1.73 m² according to the 
Modification of Diet in Renal Disease (MDRD) equation, assessed at screening or based on the 
most recent clinically relevant creatinine value if available .
 Subject has known moderate (Child -Pugh class B) or severe hepatic impairme nt (Child -Pugh 
class C).
DOSAGE AND ADMINISTRATION
During the treatment period, all subjects will receive 1 of the following 2 dose regimens:
 JNJ-63623872 600 mg bid + oseltamivir 75 mg bid on Days 1 through 7; OR
 JNJ-63623872 placebo bid + oseltamivir 75 mg bid on Days 1 through 7.
Note: For subjects who receive only 1 dose on Day 1(evening) , dosing should continue until the 
morning of Day 8 so that all subjects receive 14 doses in total.
Oseltamivir dose should be reduced to 30 mg bid for subjects with an eGFR >30 and 
≤60mL/min/1.73 m²according to the MDRD equation . Dose can be adjusted from 30 mg to 75 mg 
and vice versa during the course of treatment based on the eGFR value.
All study drugs will be taken orally . All subjects will take 2 tablets (JNJ-63623872 or placebo) and 
1capsule (oseltamivir) bid. 
PHARMACOKINETIC EVALUATIONS
All evaluations will be performed as specified in the Time and Events Schedule.
All subjects will undergo intensive PK sampling for the measurement of plasm a concentrations of 
JNJ-63623872 on Day 3, at 8 different time points within the dosing interval. The first sample should 
be collected before (preferably immediately prior to) study drug intake (≤1 hour prior tothe morning 
dose). Samples 2 to 8 should be collected at 1, 2, 4, 6, 8, 10, and 12 hours after the morning dose (and 
prior to the evening dose). For subjects who are discharged before Day 3, no intensive PK sampling 
will be performed.
All subjects will undergo sparse PK sampling for the measurement of plasma concentrations of 
JNJ-63623872 at the time points specified in the TIME AND EVENTS SCHEDULE .
Measurement of plasma concentrations of oseltamivir and oseltamivir carboxylate may be done at the 
sponsor’s discretion.
PHARMACOKINETIC/PHARMACODYNAMIC EVALUATIONS
A population PK and PK/PD analysis of plasma concentration- time data of JNJ-63623872 will be 
performed using the nonlinear mixed -effects modeling approach.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
13
Approved , Date: 19 September 2016SAFETY EVALUATIONS
Safety and tolerability will be evaluated throughout the study from signing of the ICF onwards until 
the last study -related activity. The evaluations of safety and tolerability will include monitoring of 
adverse events ( AEs)(including complications of influenz a), clinical laboratory tests, 
electrocardiograms (ECGs) , vital sign measurements, physical examinat ions, pregnancy testing, and 
assessment of specific toxicities at the time points specified in the TIME AND EVENTS 
SCHEDULE .
Any clinically significant abnormalities persisting at the end of the study/early withdrawal will be 
followed by the investigator until resolution or until a clinically stable endpoint is reached.
EFF ICACY EVALUATIONS
Patient -reported Outcomes
The impact of influenza infection and its treatment (safety and efficacy) on patient -reported symptoms 
and functioning will be evaluated at the time points specified in the TIME AND EVENTS 
SCHEDULE using Flu- iiQTMandFlu-PRO.
Viral Kinetics
Influenza viral titer will be determined and quantified in nasal MT swab staken at the time points 
specified in the TIME AND EVENTS SCHEDULE .
RESISTANCE EVALUATIONS
Viral Sequencing
Nasal MT swabs collected will be used for sequence analysis of the polymerase basic protein 2 (PB2) 
region of the influenza virus polymerase and the neuraminidase gene at the time points specified in 
the TIME AND EVENTS SCHEDULE . Exploratory sequencing of other regions of the influenza 
virus genome may also be performed.
Phenotyping
Nasal MTswabs will be used for analysis of phenotypic resistance against JNJ-63623872 and other 
antivirals at the time points specified in the TIME AND EVENTS SCHEDULE .
BIOMARKER EVALUATIONS
Blood samples will be collected at the time points specified in the TIME AND EVENTS SCHEDULE
for the exploration of blood biomarkers (eg, host ribonucleic acid [RNA], proteins including serum 
cytokines ), on the premise that these markers may play a role in the blood concentrations , treatment 
response, or safety of JNJ-63623872 or oseltamivir, or the status and change of the influenza virus 
related disease .Where local regulations permit, an optional blood sample for exploratory host DNA 
research may also be collected.
In addition, nasal swabs c ollected for other testing may be used for biomarker analyses if available.
STATISTICAL METHODS
Since this is an exploratory study, no formal sample size calculation has been performed. 
Up to 90 subjects in total will be enrolled in this study. An effort will be made to include at least
24subjects for each cohort ,with the total of subjects allowed to be recruited across both cohorts . It is 
anticipated that it is feasible to recruit at least 60 subjects, which would lead to an acceptable 
precision for the primary objective.
For age cohorts it was assumed that the number of hospitaliza tions would be about equal for elderly 
and non-elderly adults . Incase 60 subjects are enrolled, there are 40 subjects on active treatment and 
it is assumed that at least 16subjects are on active treatment in each cohort. For the comparison of PK 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
14
Approved , Date: 19 September 2016parameters of the cohort of elderly adults (test) vs.non-elderly adults (reference) with PK data in a 
16to 24 ratio and a between- subject coefficient of variation ( CV)of 60%, the 90% confidence 
interval (CI) of the geometric mean ratio (GMR) for minimum plasma concentration (Cmin) would be 
predicted to have a half-width of 35%, indicating that we can be 90% confident that thetrue GMR is 
in the interval observed GMR/1. 35 to 1.35*GMR. If 90 subjects were enrolled with 60 on active 
treatment in a 24 to 36 ratio, the predicted half -width would be 28%.
For the safety objective of the study ,the sample size of 40 to 60 subjects treated with JNJ-63623872 
can becharacterized by assessing the precisions for (potentially) observed treatment -emergent AEs. 
For example, if no related treatment -emergent serious adverse event ( SAE )is observed in a sam ple of 
60subjects exposed to JNJ-63623872, it can be concluded with 95% confidence that the true 
incidence of related treatment -emergent SAE swill be less than 5%.
The primary PK analysi s will be done on the PK-evaluable population, defined as all subjects who 
received active study treatment (JNJ-63623872 and oseltamivir), with evaluable PK measurements on 
Day 3 .
Descriptive statistics will be used for all endpoints and will be tabulated by treatment arm and age 
cohort .No formal statistical hypothesis testing will be performed. Subgroup analyses may be 
summarized descriptively u sing baseline characteristics.
Primary Endpoint
 PK parameters of JNJ -63623872 (ie, C min, Cmax, and AUC 12h) established on Day 3 .
Secondary Endpoints
1. The proportion of subjects experiencing AEs, SAEs ,and treatment -emergent grade 1-4 
laboratory abnormalities.
2. Time to return to us ual activity and usual health (Q uestion s5 and 9 of the additional items for the 
Flu-PRO). 
3. Time to significant reduction in influenza symptom severity .
4. Proportion of subjectswith a significant reduction (to mild or none for all influenza symptoms) 
at each assessment .
5. Disease status and incidence of complications associated with influenza after the start of study 
treatment , and disease progression: 
 bacterial pneumonia (culture confirmed where possible), 
 other bacterial superinfections,
 respiratory failure,
 pulmonary disease (eg, COPD), 
 cardiovascular and cerebrovascular disease (eg, myocardial infarction, CHF, arrhythmia, 
stroke).
6. D uration and seve rity of clinical symptoms as measured by the Flu- PRO .
7. Time to improvement of vital signs. 
8. Time to imp rovement of respiratory status.
9. Improvement on the ordinal scale.
10. Time to hospital discharge.
11. The time to influenza viral negativity based on qRT-PCR and/or viral culture from nasal MT 
swabs and, if applicable, based on PCR -based rapid molecular testing from nasal MT swabs.
12. Viral load over time and the rate of decline in viral load during treatment as measured by 
qRT-PCR and /orviral culture.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
15
Approved , Date: 19 September 201613. AUC of viral l oads as measured by qRT -PCR and /orviral culture. 
14. Resistance testing will be performed on all baseline samples as well as on qRT-PCR -positiv e 
post-baseline samples. Genotypic assays (sequencing of full length PB2 and other gene segments 
if applicable) will be used to determine resistance against JNJ-63623872. Phenotyping may be 
done at thesponsor’s discretion. Resistance testing for neuraminidase inhibitors will also be 
performed as applicable.
Exploratory Endpoints
1. Length of ICU stay for subjects transferred to the ICU after baseline will be collected.
2. Use of antibiotics and/or corticosteroids during hospitalization.
3. Number of subjects admitted to the ICU.
4. Correlation between the decline in viral load (measured by qRT-PCR and/or viral culture) and 
changes in clinical symptoms.
5. PK/pharmacodynamic (PD) relationship (efficacy and safety).
An independent data monitoring committee (IDMC) will be established to monitor safety and efficac y 
data on a regular basis.
An interim analysis may be performed to support regulatory activities .
Pharmacokinetic Analyses
Descriptive statistics will be calculated for plasma concentrations of JNJ-63623872 at each sampling 
time point and for the derived plasma PK parameters. Statistics include sample size (n), mean, 
standard deviation (SD), %CV, geometric mean, median, minimum, and maximum.
For each subject treated with JNJ-63623872, JNJ-63623872 plasma concentration -time data will be 
graphically present ed. Similarly, graphs of the mean plasma concentration -time profiles and overlay 
graphs with combined individual plasma concentration -time profiles will be produced. 
Pharmacokinetic parameters will be subjected to an exploratory graphical analysis in order to get a 
general overview.
Statistical analysis will be performed for the PK-evaluable population . Elderly adults (65 to 
≤85years) will be compared tonon-elderly adults (reference) to investigate the relative effect of age.
The primary PK parameters are Cmax, C min, and AUC 12h. AUC 12hwill be omitted as primary parameter 
for an age cohort if more than half of the subjects of that age cohort do not have a reliable value.
Special attention will be paid to the plasma concentrations and PK parameters of those subjects who 
have discontinued the study for an AE, or who experienced an AE of at least grade 3, o r anSAE.
Oseltamivir and oseltamivir carboxylate may be analyzed at the sponsor’s discretion.
Pharmacokinetic/Pharmacodynamic Analyses
The PK/PD relationsh ip of JNJ-63623872 exposure (AUC 12h, C max, or Cmin) with efficacy (ie, change 
in viral load from baseline and virologic response) and safety (including AEs and laboratory 
abnormalities) will be explored . Other exploratory analyses may be performed (eg, AUC of viral 
load) .
Safety Analyses
All safety endpoints will be evaluated on the Safety population, consisting of all subjects who 
received at least one dose of study drug and will be analyzed by drug received. Safety will be 
evaluated by means of AEs (including influenza complications) , clinical laboratory tests, ECGs, vital 
signs, physical examinations , pregnancy testing, and specific toxicities . The safety analysis will be 
done using descriptive statistics for the Safety population and for each study phase separately 
(treatment , follow -up, and the combination of both).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
16
Approved , Date: 19 September 2016Efficacy Analyses
The efficacy endpoints will be analyzed on the Full Analysis Set, consisting of all subjects who were 
randomized, treated and had a confirmed influenza A infection, and will be analyzed by drug 
received. Descriptive statistics will be used for all efficacy endpoi nts and will be tabulated by 
treatment arm and by age cohort. For comparisons on defined endpoints of active vs. control 
treatment ,appropriate pre-specified s tatistical analyses will be performed estimating the treatment 
difference including the associated 95% CI.
Biomarker Analyses
Statistical approaches to explore correlations between clinical outcome and blood biomarkers vary 
and depend on the different data types of the applied technology platforms, as well as on the extent of 
observed differences between study subjects. Analyses may be conducted at the sponsor’s discretion 
and reported separately from this study.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
17
Approved , Date: 19 September 2016TIME A ND EVENTS SCHE DULE –DURING HOSPITA LIZA TION (UP TO DISCHA RGE)
Phase Screening Treatment Follow -up
Day 1a2 3 4 5 6 7 10 14 28
Screening / 
BaselinebTreatmentcSafety Follow -up Visit / 
Final Study Visitd
Screening/Administrative
ICF X
Inclusion/exclusion criteria Xe
Medical history, demographics X
Physical exam X X
Symptom -directed physical exam Daily until discharge or until Day 14 (whichever comes first)
Height and weightfX
12-lead ECG XwXgX
Urine pregnancy test (female subjects of 
childbearing potential)X X X
Study Drug Administration
Randomization X
Administration of study drug (bid) XhX X X X X Xh
Virology Assessments
Nasal MT swabiforlocal PCR -based 
rapid molecular testingXk,lThe day before and/or the day of discharge from the hospitalk,m
Nasal MT swabjforcentral testing XkDaily until discharge or until Day 14 (whichever comes first)k
Efficacy/Safety Assessments
Vital signs/pulse oximetryvX 3X daily until discharge or until Day 14 (whichever comes first)nX
Influenza symptoms and impact (Flu -
iiQTM)o X X X X X X X X X X
Influenza symptoms (Flu -PRO)pX X X X X X X X X X
Hematology, chemistry, coagulation , 
serologyXqXrXrXrXr
Urinalysis X X X X X
Pharmacokinetics Xk,sXk,sXk,tXk,sXk,sXk,sXk,s
Blood biomarkers (proteins) X X X X X X X X
Blood biomarkers (mRNA) X X X X X
Biomarkers (DNA)uX
Adverse events (including 
complications of influenza)X X X X X X X X X X
Concom itant medication 
Recording X X X X X X X X X X
aDay 1 encompasses signing of the informed consent form ( ICF) approximately + 24 hours ,and can be split over 2 calendar days if needed .
bAll screening and baseline procedures should take place prior to the first study drug intake.
cDepending on the time of hospital admission and the timing of screening/baseline assessments, eligibility may only be established on the next calendar day, in which case the first study 
drug intake will be on that day, immediately after establishing eligibility .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
18
Approved , Date: 19 September 2016dSubjects who prematurely discontinue study drug treatment for any reason (except withdrawal of consent) will be asked to cont inue with their remaining study visits and assessmen t 
schedule, or, at a minimum, to return to the site for a safety follow -up visit. Subjects who withdraw consent during the treatment or follow -up phase will be offered an optional safety 
follow -up visit.
eInvestigators should ensure that all study enrollment criteria have been met at screening. If a subject’s clinical status changes (including any available laboratory results o r receipt of 
additional medical records) after screening but before the first dose of study drug is given such that they no longer meet all eligibility criteria, they should be excluded from participation in 
the study. Minimum criteria for the availability of documentation supporting the eligibility criteria are described in Section 17.4, Source Documentation.
fHeight and body weight are only to be measured at screening if not already available in the subject’s chart and if practicall y feasible.
gElectrocardiogram (ECG) to be performed approximately 4 hours after the morning dose.
hDepending on the time of screening/enrollment, subjects will receive 1 dose (evening) or 2 doses (morning and evening) of study drug on Day 1. For subjects who receive only 1 dose on 
Day 1 (evening) , dosing should continue until the morning of Day 8 so that all subjects receive 14 doses in total.
iLocal virology testing: Nasal mid-turbinate (MT) swabs should be obtained from the left and the right nostril s(from both nostrils if feasible, but from only one nostril otherwise) and 
pooled into the same collection tube . Sampling should be done at approximately the same time when required. Sampling should be done according to the local testing requirements.
jCentral virology testing: Nasal mid-turbinate (MT) swabs should be obtained from the left and the right nostril sand pooled intothe same collection tube. Sampling should be done at 
approximately the same time each day throughout the study.
kAt the time points where both nasal MT swabs and pharmacokinetic (PK) samples are obtained, these samples should be obtained as close together in time as possible. 
lAn earlier sample within 1 day before signing of the ICF can be used in lieu ofthe baseline nasal swab requirement .
mAssessment to be performed on the day of discharge from the hospital and, if possible, the day before.
nVital signs are to be measured 3 times daily: in the morning (prior to study drug intake if applicable) , approximately h alf-way in the m iddle of the day, and in the evening ( prior to study 
drug intake if applicable).
oThe Flu -iiQTM(and additional daily diary items) will be completed twice daily (preferably in the morning and in the evening) onDays 1 through 14 and once daily (preferably in the 
evening) on Days 15 through the Final Study Visit/Safety Follow -up Visit.
pThe Flu -PRO (and additional daily diary items )will be completed once daily (preferably in the evening) throughout the study.
qHepatitis A, B, and C serology te sting will be done at screening for all subjects. Follicle -stimulating hormone (FSH) will be tested at screening for female subjects who are amenorrheic 
for 12 months or less.
rIf feasible, safety blood samples will be collected after fasting for at least 10 hours.
sSparse PK sampling will be performed as follows (for as long as subjects are hospitalized) :
 on Day 1: predose (≤1 hour prior to study drug intake ), between 1.5 and 6 hours, and 12 hours after that same study drug intake (and prior to the next study drug intake). For 
subjects who start dosing in the morning of Day 1, a trough sample will be taken predose on Day 2 ( ≤1 hour prior to the morni ng dose).
 on Day 2 and Days 4 -7: predose ( ≤1 hour prior to dosing) and between 1.5 and 6 hours after the morning or evening dose (whichever is the most convenient).
tIntensive PK sampling will be performed over 12 hours: predose (≤1 hour prior to the morning dose ) and 1, 2, 4, 6, 8, 10, and 12 hours after the morning dose (and prior to the evening 
dose).Note: For subjects who are discharged before or on Day 3, no intensive PK sampling will be performed.
uThe pharmacogenomic (DNA) blood sample is optional and will preferably be collected at the baseline visit. However, if necessary eg, in case of a technical failure, it may be collected at 
a later time point without constituting a protocol deviation.
vVital signs/pulse oximetry includes also assessment of leve l of consciousness (AVPU: alert, voice, pain, unresponsive ).
wA historical ECG within 1 day before signing of the ICF can be used in lieu of the baseline ECG requirement .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
19
Approved , Date: 19 September 2016TIME A ND EVENTS SCHE DULE –AFTER DISCHA RGE FROM HOSPITA L
Note: This Time and Events Schedule should start with the Study  Day number following the day of discharge from the hospital (for 
example: subjects discharged on Study  Day9 would start with Day 10 procedures on this schedule). When subjects are discharged, the 
remainder of the study  visits should be carried out as outpatient visits (preferabl y on-site or, if not feasible, at the subject’s home) or by 
telephone follow -up as indicated in the flowchart below. Every  effort should be made to perform all of the assessm ents as outlined below 
(either on-site or at the subject’s home) ,if practically  feasible. In case of readmission to the hospital, subjects will continue to follow this 
Time and Events Schedule until the end of the study .
Phase TreatmentaFollow -up
Day 2/3/4b5
+/-1 Day6/7b8c
+/-1 Day10
+/-1 Day14
+/-2 Days28
+/-3 Days
Phone 
Follow -upOn-site/At 
homePhone 
Follow -upOn-site/At 
homeOn-site/At 
homeOn-site/At 
homeSafety Follow -up Visit / 
Final Study Visitd
On-site
Study Drug Administration
Administration of study drug (bid)aX X X
Virology Assessments
Nasal MT self-swabeforlocal PCR -based 
rapid molecular testingDaily on days with no outpatient visit
Nasal MT swab forlocal PCR -based rapid 
molecular testinge XgXg
Nasal MT swab forcentral testingfXgXgX X
Efficacy/Safety Assessments
Vital signs/pulse oximetry X X X
Physical exam X
Symptom -directed physical exam X X
12-lead ECG X
Urine pregnancy test (female subjects of 
childbearing potential)X X
Influenza symptoms and impact (Flu -
iiQTM)h X X X X X X X
Influenza symptoms (Flu -PRO)iX X X X X X X
Hematology, Chemistry, Coagulation XjXjXj
Urinalysis X X X
Pharmacokinetics Xg,kXg,k
Blood biomarkers (proteins and mRNA)lX X X
Adverse events (including complications
of influenza)X X X X X X X
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
20
Approved , Date: 19 September 2016Phase TreatmentaFollow -up
Day 2/3/4b5
+/-1 Day6/7b8c
+/-1 Day10
+/-1 Day14
+/-2 Days28
+/-3 Days
Phone 
Follow -upOn-site/At 
homePhone 
Follow -upOn-site/At 
homeOn-site/At 
homeOn-site/At 
homeSafety Follow -up Visit / 
Final Study Visitd
On-site
Concom itant medication 
Recording X X X X X X X
a If the subject is discharged while on study treatment, he/she will receive study medication for at-home use.
b Subjects do not need to be seen on these days. A telephone contact is recommended to ensure compliance with study drug intake.
cFor subjects who receive only 1 dose on Day 1 (evening), dosing should continue until the morning of Day 8 so that all subjects receive 14 doses in total.
dSubjects who prematurely discontinue study drug treatment for any reason (except withdrawal of consent) will be asked to continue with their remaining study visits and assessment 
schedule, or, at a minimum, to return to the study site for a safety follow -up visit. Subjects who withdraw consent during the treatment or follow -up phase will be offered an optional safety 
follow -up visit.
eLocal virology testing: Nasal MT self-swabbing and swab bing by site staff should only continue for subjects for which the last sample before discharge was positive . Self-swabbing and 
swabbing by site staff should be continued until the subject is confirmed influenza negative or until Day 10 at the latest. Subjects will be instructed on how to self -swab at hom e and how 
to store the nasal samples at home until their next outpatient study visit. Nasal MT (self-)swabs should be obtained from the left and the right nostril s(from both nostrils if feasible, but 
from only one nostril otherwise) and pooled into the same collection tube . Sampling should be done at approximately the same time when required. Sampling should be done according to 
the local testing requirements.
fCentral virology testing: Nasal MTswabs shoul d be obtained from the left and the right nostril sandpooled into the same collection tube. Sampling should be done at approximately the 
same time when required . Nasal MT swabs for central testing should be continued for all subjects, at the indicated time points.
g At the time points where both nasal MT swabs and PK samples are obtained, these samples should be obtained as close together in time as possible.
h The Flu -iiQTM(and additional daily diary items) will be completed twice daily (preferably in the morning and in the evening) on Days 1 through 14 and once daily (preferably in the 
evening) on Days 15 through the Final Study Visit/Safety Follow -up Visit.
iThe Flu -PRO (and additional daily diary items )will be completed once daily (preferably in the evening) throughout the study.
jIf feasible, safety blood samples will be collected after fasting for at least 10 hours.
kSparse PK sampling will be performed as follows (if practically feasible) : 
 on Day 5: at any time during the visi t.
 on Day 8: at any time during the visit.
lTwo blood samples will be taken .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
21
Approved , Date: 19 September 2016ABBREVIA TIONS
AE adverse event
AUC area under the plasma concentration -time curve
AUC 0-∞ area under the plasma concentration -time curve from time 0 to infinity
ALP alkaline phosphatase
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
ASMP Anticipated Events Safety Monitoring Plan
AST aspartate aminotransferase
AUC th area under the plasma concentration -time curve from time 0 to t hours after dosing
AVPU alert, voice, pain, unresponsive
bid bis in die; twice daily
BMI body mass index
BUN blood urea nitrogen
C0h predose plasma concentration
CDC Centers of Disease Control and Prevention
CHF congestive heart failure
CI confidence interval
Cmax maximum plasma concentration
Cmin minimum plasma concentration 
COPD chronic obstructive pulmonary disease
CPAP clinical pharmacology analysis plan
CPK creatine phosphokinase
Ctrough plasma concentration just prior to the beginning or at the end of a dosing interval
CV coefficient of variation
CYP cytochrome P450
DBP diastolic blood pressure
DNA deoxyribonucleic acid
EC 50 50% effective concentration
ECG electrocardiogram
eCRF electronic case report form
eDC Electronic Data Capture
EENT eyes/ears/nose/throat
eGFR estimated glomerular filtration rate
(e)PRO (electronic) patient reported outcome
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamyltransferase
GMR geometric mean ratio
HbsAg hepatitis B surface antigen
HCV hepatitis C virus
IC50 50% inhibitory concentration
ICF informed consent form
ICH International Conference on Harmonisation
ICU Intensive Care Unit
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IgM immunoglobulin M
INR international normalized ratio
IRB International Review Board
IV intravenous
IWRS interactive web response system
LDH lactate dehydrogenase
LS least square
MCH mean corpuscular hemoglobin
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
22
Approved , Date: 19 September 2016MT Mid-turbinate
NEWS National Early Warning Score
NOAEL no observed adverse effect level
OATP organic anion transporting polypeptide
PB2 polymerase basic protein 2
PD pharmacodynamic(s)
P-gp P-glycoprotein
PK pharmacokinetic(s)
PQC product quality complaint
PT prothrombin time
qRT-PCR quantitative reverse transcription polymerase chain reaction
QTc corrected QT interval
QTcB QT interval corrected for heart rate according to Bazett’s correction
QTcF QT interval corrected for heart rate according to Fridericia’s correction
QTcL QT correction derived by linear regression
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SBP systolic blood pressure
SD standard deviation
SUSAR suspected unexpected serious adverse reaction
tmax time to reach C max
UGT uridine diphosphate -glucuronosyltransferases
USP United States Pharm acopeia
vs. versus
WBC white blood cell
WHO World Health Organization
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
23
Approved , Date: 19 September 20161. INTRODUCTION
JNJ-63623872 (formerl y known as VX-787) is a non-nucleotide inhibitor of the polymerase 
basic protein 2 (PB2) subunit of the influenza A virus polymerase complex and is currently  in 
Phase 2 development as treatment for influenza A infection.
For the most comprehensive nonclinical and clinical information regarding JNJ-63623872 , refer 
to the latest version of the Investigator's Brochure for JNJ-63623872 .6Please consult the 
manufacturer’s prescribing information for oseltamivir (Tamiflu®) for full safet y information .14,15
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1. Background
Both seasonal and pandemic influenza are a significant cause of morbidity  and mortality  
worldwide. For example, the 2009 H1N1 influenza pandemic in the United States was 
responsible for an estimated 60.8million cases, 274,000hospitalizations, and over 
12,400deaths.9Because the efficacy  of the current annual hemagglutinin -based or modified live 
influenza virus vaccines depend son accuratel y predicting the viral strains prior to each influenza 
season or pandemic, there exists an unmet need for new antiviral agents that are broadl y 
effective.1
As well as ongoing vaccine development, several antiviral drugs have been developed for 
influenza. These drugs have been shown to shorten the duration and reduce the severit y of 
symptoms if taken early  after the onset of symptoms (within 24to 48hours). They  can also be 
taken as prophy laxis against infection. The 2main classes of antiviral drugs used against 
influenza are the neuraminidase inhibitors, such as oseltamivir (Tamiflu), peramivir 
(RapivabTM), and zanamivir (Relenza®), andthe viral M2 protein inhibitors, such as amantidine 
(Symmetrel®) and rimantadine (Flumadine®). Unfortunately , influenza strains have emerged that 
show resistance to both of these classes of drugs. In addition, these drugs have limitations in that 
they need to be administered no later than 24to 48hours after infection, and therefore many 
patients are not eligible for therap y when they  present for treatment.
A desired profile of a novel influenza antiviral includes: (1)rapid onset of protective effects 
leading to an expanded treatment window; (2)better activity  in patients with high viral load; 
(3)inhibition of both production and release of virus; (4)maintenance of potency  against 
neuraminidase -and M2-inhibitor -resistant viral strains; (5) safe and well tolerated. 
JNJ-63623872, an inhibitor of the viral replication complex, potentially  meets all of these 
criteria.
Nonclinical Studies
JNJ-63623872 hemihy drate has a molecular formula of C20H19F2N5O2•HCl•0.5 H2Oand a 
molecular weight of 399.39 Da.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
24
Approved , Date: 19 September 2016Nonclinical Pharmacology
JNJ-63623872 is a non-nucleotide inhibitor of the PB2 subunit of the influenza A virus 
polymerase complex . JNJ-63623872 is a potent inhibitor of influenza A virus replication in vitro: 
using cytopathic effect -based methods in Madin -Darb y canine kidney cells, the mean 50% 
effective concentration (EC 50) of JNJ-63623872 was 1.1 nM for a panel of 36influenza A 
strains, including contemporary  and historical H1N1 strains, including 2009 pandemic strains, 
H3N2 strains, and the highl y pathogenic H5N1 strain and H7N9 strains , as well as strains that 
were resistant to neuraminidase inhibitors. Little or no antiviral activity  was seen against 
influenza B strains. JNJ-63623872 was also effective at inhibiting viral replication in rib onucleic 
acid (RNA) based assays and in experiments using normal human bronchial epithelial cells. 
Inhibition of viral replication was observed even when JNJ-63623872 was added after the 
initiation of viral infection, and the magnitude of viral replication inhibition was largel y 
independent of multiplicity  of infection.
In vitro sy nergy /antagonism experiments show sy nergy  of JNJ -63623872 with the neuraminidase 
inhibitors oseltamivir and zanamivir, and additivity  to synergy  with favipiravir (an 
investigational nucleoside inhibitor).
In a murine model of pulmonary  influenza infection, prophy lactic treatment with JNJ-63623872 
administered at 3or 10mg/kg twice daily (bid) provided protection from influenza -induced 
mortality  and morbidity; includin g when the start- to-treat window for JNJ-63623872 was 
delay ed as long as 96hours after influenza infection. JNJ-63623872 (up to 30mg/kg) decreased 
lung viral titers (up to 1.8log 10reduction) when administered to mice 24hours after influenza A 
virus infection, and pharmacokinetic/pharmacody namic (PK/PD) analysis suggested that the 
minimum plasma concentration (Cmin) was the PK parameter driving JNJ-63623872 antiviral 
activity . The predicted minimally  efficacious therapeutic exposure assuming a 96-hour start-to-
treat window was an area under the plasma concentration -time curve from time 0to 24hours 
after dosing (AUC 24h) of approximately  3,000 ng.h/mL, with an estimated Cmin of 30ng/mL ; 
based on improved efficacy  at exposures associated with 10mg/kg regimens in the mouse 
model, 100 ng/mL is targeted as the therapeutic C min.
Nonclinical Pharmacokinetics
In vitro studies indicate that JNJ -63623872 is highly  permeable, subject to P- glycoprotein (P-gp)
transport, and is not an inhibitor of P-gpin vitro at 0.1to 100µM. JNJ-63623872 oral 
bioavailability  was high in mice and rat s, moderate in dog s, and low in monkey s.
JNJ-63623872 plasma protein binding ranged from 98% to >99.9% across species, and was 
concentration independent over a range of 1to 10μM. JNJ-63623872 was distributed widely  
throughout the body  with the exception of the brain. There was no apparent melanin binding in 
pigmented skin or ey es.
JNJ-63623872 was metabolized in rat, dog, monkey , and human hepatocy tes, and the metabolites 
detected in monkey  cells were the most similar to those detected in human cells. JNJ-63623872 
elimination was governed by both Phase I cytochrome P450 (CYP) enzymes (namel y CYP3A4) 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
25
Approved , Date: 19 September 2016and aldeh yde oxidase, as well as Phase II glucuronidation via uridine diphosphate -
glucuronosy ltransferases (UGT) 1A3 and1A9. The primary  biotransformation pathway s of 
JNJ-63623872 in rats are glucuronidation and oxidation. Based on invitro results from CYP 
enzy me induction and inhibition studies, the potential for drug -drug interactions is expected to be 
low.
The estimated systemic clearance following intravenous (IV) administration of JNJ-63623872 
was approximately  51%, 44%, and 26% of hepatic blood flow in rats, dogs, and monkey s, 
respectivel y, with an elimination half -life ranging fro m 2.7 to 21 hours.
After oral administration of 14C-JNJ-63623872 to bile duct cannulated Sprague Dawley  male 
rats, means of 79.1%, 13.7%, and 0.529% of the administered radioactivity were excreted in bile, 
feces, and urine, respectively , through 168 hours postdose.
JNJ-63623872 was found to inhibit organic anion transporting polypeptide (OATP) 1B1 with a 
50% inhibitory  concentration (IC 50) of 0.6 μM. JNJ-63623872 was also determined to be a 
substrate of OATP1B1.
Toxicology
No genotoxicity  (mutagenicity , invitro chromosomal aberration, or mammalian erythrocy te), 
phototoxicity  (in vitro), safety pharmacology  (battery  of in vitro studies designed to evaluate 
effects of JNJ-63623872 against multiple cellular targets and a batte ry of in vivo cardiovascular, 
central nervous system, and respiratory  systems), or reproductive (embry o-fetal, fertility , and 
early embry onic development) liabilities have been identified for JNJ-63623872. There were no 
toxicological effects in acute studi es in mice and rats at doses up to 1,000 mg/kg. In studies 
where rats and monkeys were administered JNJ-63623872 at very high doses for 14days, 
specific organ toxicity  (liver, kidney , bone marrow, spleen, l ymph nodes) and other toxicological 
findings were noted at doses of 250mg/kg/day  and above. The no observed adverse effect level 
(NOAEL) in 14-day, repeat -dose toxicology studies was 100 mg/kg/day  in rats and 
150mg/kg/day  in monkey s. These doses correspond to animal to human exposure multiples 
(AUC 0-24hbasis) of 40-fold and 24-fold in male and female rats, respectively , and 2-fold and 
4-fold in male and female monkey s, respectively , based on a clinical dose of 600 mg 
JNJ-63623872 bid for 5 days.
Clinical Studies
At the time of protocol writing, data were available from 4completed clinical studies: 
three Phase 1 studies and one Phase 2achallenge study . 
Human Pharmacokinetics
Food has a modest effect on bioavailability . When JNJ-63623872 was administered as either 
capsule or tablet with a high-fat meal, the AUC from time of dosing extrapolated to infinity  
(ACU 0-∞)was similar compared to fasted conditions. However, the maximum plasma 
concentration (Cmax) was decreased by 9%  for the capsule formulation and increased by 53% for 
the tablet formulation . The absolute bioavailability  of the tablet is approximately  46%.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
26
Approved , Date: 19 September 2016Following IV administration, the mean estimated volume of distribution at stead y-state is 407 L, 
much larger than ty pical blood volume, suggesting JNJ -63623872 is extensively  distributed.
Exploratory  metabolite profiling suggested that JNJ-63623872 was the major component 
circulating in the plasma and only  1 glucuronide metabolite (<5%) was identified at steady- state.
Renal elimination of unchanged JNJ -63623872 is <1% following single oral dos es.
Following single ascending doses of JNJ-63623872 capsules administered orally  in the fasted 
state to healthy  subjects, exposure (AUC) was slightly  greater than dose proportional from 
200mg to 800mg, less than dose proportional from 800mg to 1,200mg, and slightly  greater 
than dose proportional from 1,200mg to 1,600mg (study VX11-787-001) (Table 1). 
JNJ-63623872 plasma concentrations exhibit bi-phasic kinetics, eliminated initially  at a more 
rapid rate, followed by a slower terminal elimination phase. The mean terminal elimination 
half-life (t1/2term ) ranges from approximately  13 to 28 hours following single doses of 
JNJ-63623872.
Following a single 100 mg IV dose infused over 60 minutes, plasma concentrations of 
JNJ-63623872 declined more rapidl y followed by a slower terminal elimination phase. The mean 
t1/2term was 20 hours, similar to oral doses.
Table 1: Selected Single Dose JNJ -63623872 Pharm acokinetic Param eters
Mean (CV%)
StudyDose
(mg)Form ulation
Fasted/Fed Na,btmaxc
(h)Cmax
(ng/mL)AUC ∞
(ng.h/mL)t1/2term
(h)
001 200 Capsule
Fasted6 1.25
(1.00, 2.00)229 (49.6) 2,080 (50.9) 14.0 (32.3)
400 Capsule
Fasted6 3.00
(1.00, 4.00)602 (35.8) 5,690 (31.1) 12.9 (18.2)
800 Capsule
Fasted6 1.50
(1.00, 6.00)1,120 (61.8) 12,700 (41.2) 22.3 (26.9)
1,200 Capsule
Fasted6 2.50
(1.00, 4.00)1,580 (98.1) 12,500 (34.5) 17.1 (35.3)
1,600 Capsule
Fasted6 2.50
(1.00, 6.00)2,030 (83.2) 21,800 (42.8) 27.8 (60.9)
002 600 Capsule
Fasted18 2.00
(1.00, 6.00)558 (57.7) 7,856 (59.0) 20.9 (60.2)
600 Tablet
Fasted18 3.00
(1.00, 6.00)909 (45.2) 9,809 (50.5) 20.8 (78.2)
600 Tablet
Fed18 2.00
(1.00, 12.00)1,480 (71.2) 8,968 (42.8) 19.4 (16.1)
100 IV 60 -minute 
infusion8 0.75
(0.50, 1.00)1,910 (15.3) 3,580 (56.6) 20.8 (63.8)
Source: s tudies VX11 -787-001 and VX12 -787-002
aAUC ∞not reported for all subjects due to AUC extrap >25%
bterminal elimination half -life(t1/2term ) not reported for all subjects due to t 1/2exceeding last sample collection
cmedian (range)
The mean accumulation index for AUC ranged from 1.6 to 2.5 following once daily doses of 
100mg, 400 mg, and 800 mg for 10 day s. There are no apparent t ime-dependency  characteristics 
with repeat dosing. Steady -state is generall y achieved after 3 days of dosing. Pharmacokinetic 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
27
Approved , Date: 19 September 2016parameters observed in healthy  subjects appear to be similar with or without prior inoculation of 
influenza A virus in a virus cha llenge model.
Clinical Efficacy
VX11 -787-101 was a Phase 2a challenge study  with a randomized, double -blind, placebo-
controlled design. Four dose regimens of JNJ-63623872 or placebo were administered orally at 
24 hours after viral inoculation and continued for 5 consecutive day s: 100 mg once dail y, 400 mg 
once daily, and single 900mg or 1,200 mg loading dose followed by 600 mg once daily for 
5days (capsule). A total of 106healthy  subjects were enrolled and inoculated, 104 subjects 
received study  drug (n=72 JNJ -63623872; n=32 placebo).
Health y subjects were inoculated intranasall y with 1.0mL of a 50% tissue culture infective dose 
of 5.0to5.5log 10/mL live influenza A/Wisconsin/67/2005 (H3N2) challenge strain virus on 
Day 0.
Results showed that JNJ -63623872 was effective in decreasing viral shedding in subjects with an 
active influenza A infection, with a concomitant reduction in sy mptoms.
A statistically  significant dose response trend was observed on the AUC of viral shedding by 
tissue culture assay (p=0.036) and quantitative reverse transcriptase polymerase chain 
reaction (qRT -PCR) ( p=0.031).
The 1,200/600- mg treatment group had a statistically  significant reduction of the AUC of 
viral shedding by tissue culture (p=0.010) and by qRT-PCR (p=0.014) compared with 
placebo.
The 1,200/600- mg treatment group had a statistically  significant reduction of the AUC 
(p=0.040), peak (p=0.034), and duration (p<0.001) of patient -reported influenza -like 
symptom scores compared with placebo.
The 1,200/600- mg treatment group had a statistically  significant decrease in the duration 
(p=0.001) of patient -reported composite clinical sy mptom score compared with placebo.
These results suggest that JNJ-63623872 has the potential to be a novel treatment for patients 
with influe nzaA infection.
Clinical Virology
Population sequence analy ses of the PB2 segment in subjects in study  VX11-787-101 (healthy 
subjects challenged with influenza virus on Day 0, and treated with JNJ-63623872 for Days 1 
through 5) identified a variant (PB2 M431I) that was observed in multiple subjects (n=4). This 
amino acid change confers a 57-fold decrease in sensitivity  to JNJ-63623872 in in vitro studies
but the virus had reduced replication capacit y compared to wild type strains .
Additional variants at 3PB2 positions that had previously been associated with mutations that 
cause a decrease in sensitivity  to JNJ-63623872 in vitro (S324C, K376R, and M431L /R/V) were 
also observed in single JNJ- 63623872 treated subjects.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
28
Approved , Date: 19 September 2016Clinical Safety
JNJ-63623872 has been studied in single oral doses (s tudies VX11 -787-001 and VX12 -787- 002), 
multiple oral doses (studies VX11 -787-001 and VX-787FLZ1001), multiple oral doses 
coadministered with oseltamivir (study  63623872FLZ1001), and single IV doses (study 
VX12 -787-002) in healthy subjects . In addition, JNJ-63623872 has been studied in multiple oral 
doses in subjects infected with a challenge dose of influenza A (study VX11 -787-101). 
JNJ-63623872 was generally  safe and well tolerated. There were no serious adverse events 
(SAEs) or adverse events (AEs) leading to discontinuation of study  drug.
Safety  in Phase 1 studies : In health y subjects receiving single oral doses of JNJ-63623872 up to 
1,600mg once daily , multiple oral doses of JNJ-63623872 up to 800mg once daily for 10days, 
and multiple oral doses up to 600 mg bid for 10 day s, all AEs were mild in severity , except for a 
single case of moderate syncope (study VX12-787-002), and a single case of moderate diarrhea 
(study  VX-787FLZ1001). The most frequentl y occurring AEs in healthy subjects administered 
single doses of JNJ-63623872 or placebo were headache (7.9% JNJ-63623872, 7.1% placebo) 
and diarrhea (6.6% JNJ-63623872, 7.1% placebo). The most frequently occurring AEs after 
multiple doses of JNJ-63623872 up to 800 mg once dailywere also headache 
(11.1% JNJ-63623872, 16.7% placebo) and diarrhea (11.1% JNJ-63623872, 0% placebo), as 
well as somnolence (11.1% JNJ-63623872, 0% placebo). The most frequently  occurring AEs 
after multiple doses of JNJ-63623872 up to 600 mg bid for 10 d ays were gastrointestinal 
disorders, specificall y diarrhea (58.3% JNJ -63623872, 0% placebo).
There were no AEs in healthy  subjects receivin g single IV doses of 100 mg JNJ-63623872 via a 
solution of 2 mg/mL  JNJ-63623872.
Oral hormonal contraceptive is acceptable as a highl y effective user-dependent contraceptive 
method (63623872FLZ1009).
Safety  in Phase 2 studies : In 72 health y subjects inoculated with a challenge dose of influenza A 
virus receiving multiple oral doses of JNJ-63623872 (up to 1,200 mg loading dose on the first 
day followed by 600 mg once daily for an additional 4days) JNJ-63623872 was generally  safe 
and well tolerated. Adverse events occurred in 63 of 72 (87.5%) subjects who received 
JNJ-63623872, and 28 of 32(87.5%) subjects who receiv ed placebo. There were no SAEs or 
AEs leading to discontinuation of study  drug:
Influenz a-like illness was the most frequent AE (pooled placebo, 37.5%; pooled 
JNJ-63623872, 47.2%), as expected due to viral inoculation. Adverse events that occurred in 
≥10% of subjects and with ≥10% difference in the pooled JNJ-63623872 group than in the 
pooled placebo group were decreased blood phosphorus level (18.1% JNJ-63623872, 
0%placebo), rhinorrhea (4.2% JNJ-63623872, 18.8% place bo), and nasal congestion 
(1.4% JNJ-63623872, 15.6% placebo).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
29
Approved , Date: 19 September 2016The majorit y of AEs that occurred in subjects treated with JNJ-63623872 were mild or 
moderate in severity . Some of the AEs were severe; 8 severe AEs occurred in 5subjects 
treated with JNJ-63623872: decreased blood phosphorus (n=4); increased blood creatine 
phosphokinase (CPK) (n=1); increased blood myoglobin (n=1); and severe headache (n=2). 
The most frequent AEs considered possibl y related to study  drug in the pooled 
JNJ-63623872 group were increased alanine aminotransferase (ALT, 12.5%), decreased 
blood phosphorus (12.5%), and increased aspartate aminotransferase (AST, 5.6%). Both 
ALT elevation and serum phosphorus decrease have been previously  described in influenza 
and other upper respir atory  tract infections.
1.2. Oseltamivir
Oseltamivir (Tamiflu )
Oseltamivir is an influenza neuraminidase inhibitor indicated for the treatment of acute, 
uncomplicated influenza infection in patients 2 weeks of age and older who have been 
symptomatic for no more than 2 days and for prophy laxis of influenza in patients 1 year and 
older.
Clinical studies have shown that treatment with oseltamivir has clinical and virological benefit in 
patients with uncomplicated influenza when administered within 48 hour s of onset of symptoms. 
Randomiz ed studies in patients with severe influenza are lacking, but observational studies in 
patients admitted to hospital suggest that oseltamivir treatment, especially  if it is given early, is 
associated with reduced mortality  and shorter length of stay .3
Higher oseltamivir doses were tested in patients with uncomplicated influenz a, but clinical or 
virological outcomes were found not significantly  different compared tothe standard dose. 
Despi te a lack of evidence, several health authorities, including the United States Centers of 
Disease Control and Prevention (CDC) are recommending theuse of double dose oseltamivir for 
severe lyill or immunocompromised with influenza .13
There have been no studies specificall y designed to evaluate the effectiveness of extending the 
duration of oseltamivir treatment beyond 5 days, however, it is reported in literature that over 
32% of hospitalized patients carry replicating virus beyond 7 days of illness onset.7Using  
mathematical simulations tomodel an early  or extended -duration oseltamivir therap ybeyond 
5days has shown anincreased virological and symptom efficacy and a potential for reduced 
emergence of resistance . The available data from uncomplicated influenza studies are 
inconclusive whether reducing viral shedding leads to faster clinical improvement, but there are 
data support ingthat lower viral load results in faster symptom resolution.7Thus, there may be a 
possible benefit in using oseltamivir beyond 5 days in patients hospitalized with influenza.
For treatment of uncomplicated influenza in adults, oseltamivir is administered as 75 mg bid for 
5days without respect to food.14,15The dose is reduced in the presence of significant renal 
insufficiency . The most common AEs associated with oseltamivir (>1% and more common than 
with placebo) are nausea, vomiting, diarrhea, and abdominal pain. These events were generall y 
mild to moderate and usually  occurred on the first 2 days of administration. Subjects with 
influenza, including those receiving oseltamivir, may experience confusion and abnormal 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
30
Approved , Date: 19 September 2016behavior early in the course of illness. Serious skin/hy persensitivity  reacti ons may occur with 
oseltamivir. Less than 1% of subjects discontinued prematurel y from clinical studies due to 
nausea and vomiting. 
Oseltamivir should not be administered until 2 weeks after intranasal live influenza 
immunization. Live influenza virus immunization should be delay ed until 2 days after 
discontinuation of oseltamivir.
Oseltamivir is metabolized to oseltamivir carboxylate, which is pharmacologicall y active and 
entirely  eliminated in the urine. Clinically  significant drug interactions are unlikely .Plasma 
concentrations of the active metabolite are proportional to oseltamivir dose and display  a small 
degree of inter-individual variability . Stead y-state plasma concentrations were achieved within 
3days of administration of multiple doses. On the basis of AUC, there is less than 2-fold 
accumulation of the active metabolite during twice daily administration. Pharmacokinetic 
parameters after 1 week of administration of multiple doses provided no indica tion of a temporal 
change in the disposition of the active metabolite over time.
Following doses of 600 mg of JNJ-63623872 bid for 10 days, mean Cmaxand AUC 12hof 
JNJ-63623872 were, respectivel y, 1.2 -fold and 1.8 -fold higher on Day  10 compared with Day  1.6
JNJ-63623872 600 mg bid administered alone or in combination with oseltamivir 75 mg bid for 
5 days resulted in generally  comparable values for JNJ-63623872 predose plasma concentration 
(C0h) on Days 3, 4, and 5, indicating that near steady -state conditions had been achieved prior to 
Day 3. For JNJ-63623872 administered alone versus in combination with oseltamivir, C minand 
AUC 12hof JNJ-63623872 were comparable, while JNJ-63623872 C maxwas 1.3-fold higher when 
administered in combination with oseltamivir, compared with administration of JNJ-63623872 
alone. The median time to reach C max(tmax) of JNJ-63623872 was 3.0 hours when JNJ -63623872 
was administered alone and 1.5 hours when administered in combination with oseltamivir. For 
oseltamivir administered alone versus in combination with JNJ-63623872, oseltamivir AUC 12h
and oseltamivir carbox ylate Cmin, C max, and AUC 12hwere comparable. Oseltamivir Cminwas 
1.1-fold higher and Cmax was 5% decreased when administered in combination with 
JNJ-63623872, compared with oseltamivir administered alone.6
For further information regarding oseltamivir refer to the manufacturer’s prescribing 
information .14,15
1.3. Overall Rationale for the Study
Although generally  a  s elf-limited disease, infection with influenza A can cause significant 
morbidity  and mortalit y, especiall y in certain patient population s such as those at the extremes of 
age, and may result in hospitalization. Currently  available antiviral therapies (oseltamivir [oral], 
zanamivir [inhaled] and peramivir [IV]) are not indicated for influenza in hospitalized patients; 
however, they are used as de-facto standard of care as recommended by the CDC and the World 
Health Organization (WHO) for this patient population. Another class of influenza antiviral 
drugs, the adamantanes, is also available but is associated with high levels of antiviral resistance 
among circulating influenza viruses. 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
31
Approved , Date: 19 September 2016The objective of antiviral therapy  is to suppress viral replication rapidly  and effectivel y, and thus 
provide a clinical benefit. Patients hospitalized with influenza are more severel y ill and are 
reported to shed virus longer compared to patients with uncomplicated disease who are 
ambulatory . JNJ-63623872 has been demonstrated to neutralize a broad array  of influenza A 
viruses both in in vitro and in vivo nonclinical models and has shown to reduce peak viral loads, 
AUC of viral shedding, and influenza -related clinical symptoms in an expe rimental human 
challenge model . A Phase 2b dose -ranging study  evaluating JNJ-63623872 in adult subjects with 
uncomplicated seasonal influenza A infection is ongoing (VX14-787 -103;63623872FLZ2001 ). 
The purpose of the current study  is to evaluate the pharmacokinetics (PK), safety , and antiviral 
effect of JNJ-63623872 in elderly  hospitalized subjects (aged 65 to ≤85 years) as compared to
adult (aged 18 to ≤64 y ears) hospitalized subjects with influenza A following a 600 mg bid 7- day 
therap y.
In a mouse model of influenza infection, a concentration of 30 ng/mL  was associated with effects 
on lung viral titers which were superior to those seen with oseltamivir, and 100 ng/mL was 
associated with even greater reductions in lung viral titers. Study  63623872FLZ1001 
(VX787FLZ1001), a healthy  adult volunteer drug -drug interaction and PK study , showed, in -line 
with previous PK modeling data, that JNJ-63623872 at a dose level of 600mg bid resulted in a 
median C12hof 161 ng/mL  following the first dose and 310 ng/mL at stead y-state. In this 
exploratory  study , the dose regimen of 600 mg bid is expected to result in antiviral activity  and a 
good safet y profile.
1.4. Benefits and Risks Management
Please see Section 1.2and the manufacturer’s prescribing information14,15for the benefits and 
risks of oseltamivir.
1.4.1. Know n Benefits of JNJ -63623872
The clinical benefit of JNJ -63623872 remains to be established.
1.4.2. Potential Benefits of JNJ- 63623872
Results from JNJ-63623872 clinical studies may be useful in developing a new therap y for 
influenza A infection.
The dose regimen of 600mg bid is expected to result in antiviral activity and subjects may 
benefit from participating in this study .
1.4.3. Know n Risks of JNJ -63623872
Every  medication can have undesirable effects.
Adverse events in healthy subjects : Based on the data available, only headache and diarrhea 
were seen consistently  in healthy  subjects and were considered by the investigator to be possibly  
related to JNJ-63623872 treatment. These events were generall y mild to moderate. The 
occurrences of headache were equall y distributed among JNJ-63623872 and placebo, while 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
32
Approved , Date: 19 September 2016diarrhea occurred more often after treatment with JNJ-63623872 compared to placebo. In 
subjects inoculated with influenza A virus in a challenge model of influenza A, transient 
elevations of liver transaminases, predominantl y ALT, and decreased blood phosphorus were 
observed following JNJ-63623872 exposure.
1.4.4. Potential Risks of JNJ -63623872
Reproductive Risk and Pregnancy
Based on preclinical studies, no reproductive (embry o-fetal, fertility  and early embry onic 
development) liabilities have been identified for JNJ-63623872 .
In the current study , subjects who are heterosexually  active must follow the contraception 
requirements detailed in Section 4.3. Subjects who are pregnant, or breastfeeding, or planning to 
become pregnant during this study  or within 90 days after receiving the last dose of study  drug, 
or are unwilling to use an acceptable method of contraception are not allowed to enter this study 
(see Section 4.2). Subjects’ study  treatment will be discontinued if they become pregnant (see 
Section 12.3.3 ).
Potential Toxicity
No genotoxicity  (mutagenicity , invitro chromosomal aberration, or mammalian erythrocy te), 
phototoxicity  (in vitro), or safet y pharmacology  (battery of in vitro studies designed to evaluate 
effects of JNJ-63623872 against multiple cellular targets and a battery  of in vivo cardiovascular, 
central nervous system, and respiratory  systems) liabilities have been identified for 
JNJ-63623872. There were no toxicological effects in acute studies in mice and rats at doses up 
to 1,000mg/kg. In studies where rats and monkey s were administered JNJ-63623872 at very 
high doses for 14 days, specific organ toxicity  (liver, kidney , bone marrow, spleen, ly mph nodes ) 
and other toxicological findings were noted at doses of 250mg/kg/day  and above. The NOAEL 
in 14-day, repeat -dose toxicology  studies was 100mg/kg/day  in rats and 150mg/kg/day  in 
monkey s.These doses correspond to animal to human exposure multiples (AUC 0-h basis) of 
40-fold and 24-fold in male and female rats, respectively , and 2-fold and 4-fold in male and 
female monkey s, respectively , based on a clinical dose of 600 mg bid for 5 day s.
Based on human experience to date at high doses (up to 1,600mg) no toxicology  findings were 
observed, however this study  will include study  withdrawal criteria for individual subjects as a 
precaution (see Section 10.2, Discontinuation of Study  Treatment ).
1.4.5. Overall Benefit/Risk A ssessment
Based on the available data and proposed safet y measures, the overall benefit/risk assessment for 
this study  is acceptable for the following reasons:
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
33
Approved , Date: 19 September 2016JNJ-63623872 has been studied inhealthy  subjects receiving single oral doses of 
JNJ-63623872 up to 1,600mg (studies VX11 -787-001 and VX12 -787-002), multiple oral 
doses of JNJ-63623872 up to 800mg once daily  for 10 days (study VX11 -787-001), 
multiple oral doses of JNJ-63623872 of 600mg bid up to 10 days (study VX-787FLZ1001), 
and single IV doses of 100mg JNJ-63623872 (study VX12-787-002), and in healthy 
subjects infected with a challenge dose of influenza A receiving multiple oral doses of 
JNJ-63623872 (up to 1,200 mg loading dose on the first day followed by 600 mg once daily 
for an additional 4days) (study VX11 -787-101). JNJ-63623872 was generally  safe and well 
tolerated.
Only  subjects who meet all of the inclusion criteria and none of the exclusion criteria (as 
specified in the protocol) will be allowed to participate in this study . The selection criteria 
include adequate provisions to minimize the risk and protect the well- being of subjects in 
the study .
Safety  will be closel y monit ored by the investigator throughout the study . Safet y and 
tolerability  assessments (including vital signs, electrocardiogram [ECG], physical 
examination, clinical laboratory  tests, and assessment of AEs or SAEs) will be performed at 
scheduled visits throug hout the study .
Several safety  measures have been proposed to minimize potential risks to subjects, 
including:
A safety  management plan is in place for subjects experiencing specific toxicities such 
as allergic reactions, clinical hepatitis, renal complica tions, nausea, and diarrhea.
The safet y margins for the projected exposures calculated from non-clinical toxicology 
studies in monkey s warrant close laboratory  monitoring during the study , thus samples 
for clinical laboratory  tests will be collected throug hout the study . Elevations of liver 
enzy mes (eg, AST, ALT, bilirubin, gamma -glutam yltransferase [GGT], alkaline 
phosphatase [ALP]), hematological changes, serum creatinine elevations, and presence 
of proteinuria/albuminuria will be closel y monitored.
Utilization of withdrawal criteria (see Section 10.2).
Pregnancy  and breastfeeding are exclusion criteria for all clinical studies conducted to 
date. All subjects are required to use contraceptive methods as detailed in the protocol.
An independent data monitoring committee (IDMC) will be established to monitor 
safet y and efficacy data on a regular basis.
Oseltamivir is a widely used medication for the treatment of influenza A infection in 
patients 2 weeks of age and older . Please see Section 1.2and the manufacturer’s prescribing  
information14,15for the benefits and risks of ose ltamivir.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
34
Approved , Date: 19 September 20162. OBJECTIVES A ND HYPOT HESIS
2.1. Objectives
Primary Objective
The primary  objective is to evaluate the PK parameters of JNJ-63623872 in combination with 
oseltamivir in elderly  subjects (aged 65 to ≤85 years) compared to adults (aged 18 to ≤64 years)
with influenza A infection .
Secondary Objectives
Secondary  objectives include the assessment of the following parameters in the JNJ-63623872 
treatment arm compared to the control arm:
1.Safety  and tolerability .
2.The time to influenza viral negativit y based on q RT-PCR and/or viral culture from nasal 
mid-turbinate (MT) swabs and, if applicable, based on PCR- based rapid molecular testing 
from nasal MT swabs.
3.Viral load over time and rate of decline in viral load during treatment as measured by 
qRT-PCR and/or viral culture.
4.AUC of viral load as measured b y qRT -PCR and/or viral culture.
5.Disease status and incidence of complications associated with influenza after the start of 
study  treatment , and disease progression:
bacterial pneumonia (culture confirmed where possi ble),
other bacterial superinfections,
respiratory  failure,
pulmonary  disease (eg, asthma, chronic obstructive pulmonary  disease [COPD]), 
cardiovascular and cerebrovascular disease (eg, myocardial infarction, congestive heart 
failure [CHF], arrh ythmia, stroke).
6.Change in duration an d severit y of clinical s ymptoms as measured b y the Flu -PRO .
7.Time to improvement of vital signs.
8.Time to improvement of respiratory  status.
9.Improvement on the ordinal scale.
10.Emergence of drug resistance as detected b y genotype or phenot ype.
11. Time to return to premorbid functional status.
12.Time to hospital discharge.
Exploratory Objectives
Exploratory  objectives include the assessment of the following param eters in the JNJ-63623872 
treatment arm compared to the control arm:
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
35
Approved , Date: 19 September 20161.Use of antibiotics and/or corticosteroids during hospitalization .
2.Number of subjects admitted to the I ntensive Care Unit (I CU).
3.Length of ICU stay  for subjects transferred to the ICU aft er baseline.
4.Correlation between the decline in viral load (measured by qRT-PCR and/or viral culture) 
and changes in clinical symptoms .
5.PK/PD relationship (efficacy  and safet y).
2.2. Hypothesis
No formal h ypothesis will be tested.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview of Study  Design
This is a randomized, double -blind, placebo -controlled, multicenter Phase 2 study  to evaluate the 
effect of JNJ-63623872 600 mg bid versus (vs.) placebo, both in combination with oseltamivir 
75mg bid in adult and elderly  hospitalized subjects with influenza A infection. Up to 90 subjects 
in total will be enrolled in this study . An effort will be made to enroll a minimum of 
approximately  24subjects per age cohort (adults aged 18 to ≤64 years and elderl y people aged
65 to ≤85 y ears).
Subjects who meet all eligibility  criteria will be randomized in a 2:1 ratio to receive 1 of the 
following 2 treatments:
JNJ-63623872 600 mg bid + oseltamivir 75 mg bid ; OR
JNJ-63623872 p lacebo bid + oseltamivir 75 mg bid
Oseltamivir dose should be reduced to 30 mg bid for subjects with an estimated glomerular 
filtration rate (eGFR ) >30 and ≤60mL/min/1.73 m²according to the Modification of Diet in 
Renal Disease (MDRD) equation . Dose can be adjusted from 30 mg to 75 mg andvice versa 
during the course of treatment based on the eGFR value.
All study  drug swillbe taken orally. 
The study  will consist of a screening/ baseline visit, a double -blind treatment period of 7days, 
and a follow -up period of 21days.
The entire study  duration for each subject will be 28days with study  assessments daily  during 
the treatment period, and on Days 10, 14, and 28 of the follow -up period. The study  is 
considered complete with the completion of the last study  assessment for the last subject 
participating in the stud y.
Full plasma concentration -time profiles of JNJ-63623872 will be determined over 12hours after 
the morning dose of study  drug on Day 3. For subjects who are discharged before Day 3, no 
intensive blood sampling will be performed. Sparse plasma samples for the measurement of 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
36
Approved , Date: 19 September 2016plasma concentrations of JNJ-63623872 will be taken on Days1, 2, 4through 7during 
hospitalization, and on Days 5 and 8 after discharge (see Section 9.2, Pharmacokinetics ).
Measurement of plasma concentrations of oseltamivir and oseltamivir carbox ylatemay be done 
at the sponsor’s discretion.
Safety  and tolerability  will be assessed throughout the study  from signing of the Informed 
Consent Form (ICF) until the subject’s last study -related activity .Safet y evaluations will include 
the monitoring of AEs (including complications of influenza ), clinical laboratory  tests, 12 -lead 
ECGs, vital sign measurements, (symptom -directed) physical examinations, pregnancy  testing , 
and specific toxicities ( see Section 9.3, Safet y Evaluations ). 
Influenza symptom score, impact of influenza, and functional status will be assessed , and 
samples for viral titers and viral sequencing will be collected (see Section 9.4.1 , Evaluations).
Blood samples will be collected to allow for the exploration of blood biomarkers (see 
Section 9.5).Where local regulations permit, an optional biomarker sample may be collected at 
baseline for host deoxy ribonucleic acid (DNA) genoty ping (see Section 9.7, Sample Collection 
and Handling ).
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study . Refer 
toSection 11.8,Data Monitoring Committee, for details.
3.2. Study Design Rationale
Blinding, Control, Study Phase/Periods, Treatment Arms
A placebo control will be used to establish the frequency  and magnit ude of changes in clinical 
endpoints that may occur in the absence of active treatment. Randomization will be used to 
minimize bias in the assignment of subjects to treatment arms , to increase the likelihood that 
known and unknown subject attributes (eg,demographic and baseline characteristics) are evenl y 
balanced across treatment arms , and to enhance the validity  of statistical comparisons across 
treatment arms . Blinded treatment will be used to reduce potential bias during data collection and 
evaluation of clinical endpoints.
Dose Selection
To date, three Phase 1 and one Phase 2 clinical studies have been completed. In the Phase 1 
studies, a total of 128 healthy  subjects were exposed to JNJ- 63623872, receiving: 
a single oral dose of JNJ-63623872 ranging from 50 to 1,600 mg (studies VX11 -787-001 
and VX11 -787-002, N=42), 
four single doses of 100 mg JNJ- 63623872 (study  VX11 -787-001, N=16),
10-day multiple oral doses of JNJ-63623872 once daily  ranging from 100 to 800 mg (study  
VX11 -787-001, N=18), 
three single doses of 600 mg JNJ -63623872 (study  VX12 -787-002, N=18),
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
37
Approved , Date: 19 September 2016single IV doses of 100 mg JNJ -63623872 (study  VX12-787-002, N=8 previously  exposed to 
single doses of 600 mg), 
5-day multiple oral doses of JNJ-63623872 600 mg bid , alone or in combination with 
oseltamivir 75 mg (study 63623872FLZ1001, N=18; 4 additional subjects received up to 4 
doses of 300 mg JNJ -63623872 twice dail y), 
10-day multiple oral doses of JNJ -63623872 600 mg bid(study  63623872FLZ1001, N=12).
In the Phase 2 study , 72 healthy  subjects challenged with influenza A received multiple oral 
doses of JNJ-63623872, with a loading dose up to 1,200 mg on the first day followed by up to 
600mg once daily for an additional 4days (study VX11-787-101). JNJ-63623872 was generall y 
safe and well tolerated in these studies and no SAEs or AEs leading to discontinuation were 
observed . In addition , there were no clinically  significant changes in standard 12-lead ECG s, 
vital signs, and clinical laboratory  tests.
In an ongoing Phase 2b study  (VX14 -787-1 03; 63623872FLZ2001 ), the selected doses of 
JNJ-63623872 are 300 and 600mg bid (without a loading dose). These doses were selected 
based on modeling and simulation.9Target concentrations of 30 and 100ng/mL  have previously 
been identified based on efficacy  data in a mouse model of influenza infection, in which 
30ng/mL  was associated with better efficacy  compared to oseltamivir, and 100 ng/mL  result ed 
in even greater reduction in viral load in the lungs. Simulations were performed to predict 
attainment of these target concentrations in patients. The probability  of target attainment for 
simulated doses was compared to that of the highest dose evaluate d in study VX11-787-101 
(1200/600 mg once daily), at which a statistically  significant improvement in viral shedding and 
clinical symptom scores was observed compared to placebo. The median plasma concentration 
just prior to the beginning or at the end of a dosing interval (Ctrough) in the 1200/600 mg once 
daily  dose group was approximately  130 to 150ng/mL across the 5-day dosing duration. Twice 
daily  doses were simulated with the goal of maintaining a higher Ctrough without increasing the 
overall exposure or AUC .
In the current proposed study , JNJ-63623872 600 mg bid will be administ ered for 7daysto 
subjects infected with influenza A.
Host DNA and Biomarker Collection
Blood samples will be collected to allow for the exploration of blood biomarkers (eg, proteins, 
host RNA) on the premise that these markers may play a role in the blood concentrations , 
efficacy  or safet y of JNJ -63623872 or oseltamivir ,or help to explain interindividual variability  in 
clinical outcomes or may help to identify  population subgroups that respond differently  to 
treatment. The biomarker analyses may also help to evaluate the PD of JNJ-63623872 and 
oseltamivir, and aid in eva luating the drug clinical response relationship. Where local regulations 
permit, an optional blood sample for exploratory  host DNA research may  also be collected.
DNA and biomarker samples may be used to help address emerging issues and to enable the 
devel opment of safer, more effective, and ultimately  individualized therapies. 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
38
Approved , Date: 19 September 20164. SUBJECT POPULA TION
Signing of the ICF needs to be done before the first study -related activity .
Screening for eligible subjects will be performed on Day 1, before the randomization and the 
first administration of study  drug. Note: Day 1 encompasses signing of the ICF approximatel y 
+ 24 hours, and can be split over 2 calendar days if needed. Depending on the time of hospital 
admission and the timing of screening/baseline assessments, eligibility  may only be established 
on the next calendar day, in which case the first study  drug intake will be on that day, 
immediately  after establishing eligibility .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, the 
investigator should consult with the appropriate sponsor representative before enrolling a subject 
in the study . 
For a discussion of the statistic al considerations of subject selection, see Section 11.2, Sample 
Size Determination.
4.1. Inclusion Criteria
Each potential subject must satisfy  all of the following criteria to be enrolled in the study .
1. Subject requires hospitalization to treat influenza infection and/or to treat complications 
of influenza infection.
2. Subject tested positive for influenza A infection within 1 dayof signing ofthe ICF using 
a PCR -based rapid molecular diagnostic assay .
3.Subjects must be capable of swallowing stud y medication tablets and capsules.
4.Subject must be male or female 18to 85 y ears of age, inclusive. 
5.Each subject (or their legall y acceptable representative) must sign an ICF indicating that 
he or she understands the purpose of and procedures required for the study  and is willing  
to participate in the study .
6.Subject must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol (see Section 4.3, Prohibitions and Restrictions ).
7.Before randomization, a female subject must be either:
a.Not of childbearing potential:
i.postmenopausal (>45 years of age with amenorrhea for at least 12 
months);
ii.permanentl y sterilized (eg, bilateral tubal occlusion [which includes tubal 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
39
Approved , Date: 19 September 2016ligation procedures as consistent with local regulations], hysterectomy, 
bilateral salpingectom y, bilateral oophorectomy);
iii.or otherwise incapable of pregnancy .
b.Of childbearing potential and 
i.practicing effective method sof birth control consistent with local 
regulations regarding the use of birth control methods for subjects 
participating in clinical studies
ii.and agree sto continue using twomethod sof birth control throughout the 
study  and for at least 90days after receiving the last dose of study  drug 
(see Section 4.3,Prohibitions and Restrictions)
8.A female subject of childbearing potential must have a negative urine pregnancy  test at
screening.
9.A female subject must agree not to donate eggs (ova, oocy tes) for the purposes of 
assisted reproduction throughout the study  and for at least 90days after receiving the last 
dose of study  drug (see Section 4.3, Prohibitions and Restrictions).
10.A male subject who is sexually  active with a woman of childbearing potential and has not 
had a vasectom y must agree to use effective method sof birth control (see Section 4.3, 
Prohibitions and Restrictions) , and all male subjects must also not donate sperm during 
the study  and for 90days after receiving the last dose of study  drug.
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded f rom participating 
in the study .
1. Subject received more than 3 doses of theinfluenza antiviral medication oseltamivir, 
zanamivi r, or peramivir since the start of the influenza symptoms, or ribavirin within 
6months prior to screening.
2. Subject is unwilling to undergo regular nasal MT swab sor has any physical abnormalit y 
which limits the ability  to collect regular nasal specimens.
3. Subject is known (considering lab results of the past 6 months) tobe severel y 
immunocompromised as defined by a CD4+count <350 cells/mm3or an absolute 
neutrophil count < 750/mm3.
4.Subject is undergoing p eritoneal dialy sis, hemodialy sis, or hemofiltration.
5. Subject has an eGFR ≤30 mL/min/1.73m ² according to the MDRD equation, assessed at 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
40
Approved , Date: 19 September 2016screening or based on the most recent clinicall y relevant creatinine value if available.
6. Subject has known moderate (Child -Pugh class B) or severe hepatic impairment (Child -
Pugh class C). 
7. Subject has presence of any pre-existing illness, clinically  significant laboratory 
abnormalities, ECG findings ,or physical examination findings that, in the opinion of the 
investigator, would place the subject at an unreasonabl y increased risk through 
participation in this study . The investigator should consider the laboratory parameter 
criteria for study  drug discontinuation (see Section 9.3.6 ) when screening a subject for 
enrollment .
8. Subject with known acute hepatitis A, B, or, C virus infection at screening , or known 
chronic hepatitis C infection undergoing antiviral therap y.
9. Subject has known allergies, hypersensitivity , or intolerance toJNJ-63623872 or its 
excipients (refer to the Investigator's Brochure6).
10. Subject has contraindications to the use of oseltamivir per local prescribing 
information.14,15
11. Subject has received an investigational drug (including investigational vaccin es) or used 
an invasive investigational medical device within 30 days, or has received an 
investigational biological product within 3months or 5 half-lives (whichever is longer) 
before the planned first dose of study  drug or is currentl y enrolled in an investigational 
study .
12. Subject has a history  ofclinically  significant heart arrhythmias , eg,unstable angina or 
myocardial infarction; uncontrolled, unstable atrial arrhythmia ,or sustained ventricular 
arrhythmia ,or a history  of risk factors for Torsade d e Pointes sy ndrome.
13. Subject has taken any disallowed therapies as noted in Section 8, Pre-study  and 
Concomitant Therap y before the planned first dose of study drug.
14. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, or a 
family  member of an employ ee or the investigator , or an emplo yee of the sponsor.
15.Female subject who is pregnant, or breastfeeding, or planning to become pregnant while 
enrolled in this study  or within 90days after the last dose of study  drug, or female subject 
of childbearing potential who is unwilling to use an acceptable method of contraception 
as outlined in Section 4.3, Prohibitions and Restrictions.
16.Male subject who plans to father a child while enrolled in this study  or within 90days 
after the last dose of study  drug.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
41
Approved , Date: 19 September 201617. Subject has any condition for which, in the opinion of the investigator , participation 
would not be in the best interest of the subject (eg, compromise the well-being) or that 
could prevent, limit, or confo und the protocol -specified assessments .
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including available laboratory results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given such 
that he or shenolonger meet sall eligibility  criteri a, then the subject should be excluded from 
participation in the study . Section 17.4, Source Documentation, describes the required 
documentation to support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subject s must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. F emale subject sof childbearing potential who are heterosexually  active must remain on 
effective methodsof birth control throughout the study  and for at least 90days after the 
last dose of study  drug, and all female subjects must also agree not to donate eggs (ova, 
oocy tes) throughout the study  and for 90days after receiving the last dose of study  drug . 
Effective methods of birth control include use of an intrauterine device or hormone -
based contraception in combination with a barrier contraceptive (eg, male condom, 
diaphragm with spermicidal gel, cervical cap, or female condom) , or practice 
hetero sexual abstinence . Female subjects of childbearing potential having a 
vasectomized partner are required to use one barrier contraceptive method throughout 
the study  and for at least 90days after the last dose of study  drug when heterosexually 
active.
Note: A male and female condom should not be used together due to risk of breakage or 
damage caused b y latex friction.
Note: If the childbearing potential changes after start of the study  (eg, female subject 
who is not heterosexually  active becomes active), the subject must use effective 
method sof birth control, as described above throughout the study  and for 90days after 
thelast dose of study  drug .
2. M ale subject swho are sexually  active with a woman of childbearing potential and have 
not had a vasectomy  must use effective methods of birth control as described above , and 
all male subjects must also not donate sperm throughout the study  and for90 daysafter 
receiving the last dose of study  drug.
If the female sexual partner is postmenopausal for at least 2 years, is permanentl y 
sterilized (eg, hysterectomy , bilateral salpingectomy , bilateral oophorectom y), or 
otherwi se incapable of becoming pregnant, the birth control methods mentioned are not 
applicable. If the female sexual partner has had a tubal ligation, at least one 
contraceptive method should be used.
Male subjects who had a vasectom y and have a female partner of childbearing potential 
must agree to use a male condom throughout the study  and for 90daysafter receiving 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
42
Approved , Date: 19 September 2016the last dose of study  drugs.
Note : A male and female condom should not be used together due to risk of breakage or 
damage caused by latex fricti on.
3. Subject should refrain from taking any disallowed therapies as noted in Section 8, Pre-
study  and Concomitant Therap y.
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Procedures for Ran domization and Stratification
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2treatment arms in a 2:1 ratio (active vs. placebo) based on a computer -generated 
randomization schedule prepared before the study  by or under the supervision of the sponsor. 
The randomization will be balanced by  using randomly  permuted blocks and will be stratified by  
agecohort . An interactive web response system (IWRS) will assign a unique treatment code, 
which will dictate the treatment assignment and matching study  drug kit for the subject. The 
requestor must use his or her own user identification and personal identification number when 
contacting the IWRS, and will then give the relevant subject details to uniquely  identify  the 
subject.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (ie, study  drug plasma
concentrations ) will be handled with special care to ensure that the integrity  of the blind is 
maintained and the potential for bias is minimiz ed. This can include making special provisions, 
such as segregating the data in question from view by the investigators, clinical team, or others 
as appropriate until the time of database lock and unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be dictated by knowing the treatment status of the 
subject. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  contacting the IWRS. It is recommended that the investigator contact the sponsor or 
its designee if possible to discuss the particular situation, before breaking the blind. Telephone 
contact with the sponsor or its designee will be available 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date, time, 
and reason for the unblinding must be documented by the IWRS, in the appropriate section of the 
electronic case report form (eCRF ), and in the source document s. The documentation received 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
43
Approved , Date: 19 September 2016from the IWRS indicating the code break must be retained with the subject's source documents in 
a secure manner .
6. DOSA GEAND ADMI NISTRA TION
During thetreatment period, all subjects will receive 1 of the following 2 dose regimens:
JNJ-63623872 600 mg bid + oseltamivir 75 mg bid on Day s 1 through 7; OR
JNJ-63623872 placebo bid + oseltamivir 75 mg bid on Day s 1 through 7.
Note:For subjects who receive only  1 dose on Day  1(evening) , dosing should continue until the 
morning of Day  8 so that all subjects receive 14 doses in total.
Oseltamivir dose should be reduced to 30 mg bid for subjects with an eGFR >30and 
≤60mL/min/1.7 3m²according to the MDRD equation . Dose can be adjusted from 30 mg to 
75mgand vice versa during the course of treatment based on the eGFR value.
Study  drugs(JNJ-63623872 or placebo + oseltamivir) will be administered according to the 
following guidelines:
All study  drugs willbe taken together orally .All subjects will take 2 tablets (JNJ-63623872 
or placebo) and 1 capsule (oseltamivir) bid.
The first dose of study drugswill be administered on Day 1 (ie, signing of the ICF 
approximately  + 24 hours) at the study  site after screening assessments and randomization
have been performed .Depending on the time of randomization and the time of first study  
drug intake on Day 1, subjects may receive 1 or 2doses of study  drug on Day 1.Subjects 
may delay or bring forward administration of the second dose (by no more than 4 hours) 
only if the nominal timing for this second dose falls in the middle of the night.
Subjects will swallow the study  drug whole and will not chew the drug before swallowing. 
Opening capsules or crushing tablets in food or water is not permitted.
Study drug will be a dministered as described in the TIME AND EVENTS SCHEDUL E. All 
intakes of study  drug will take place at the study  site for as long as subjects are hospitalized. 
Study -site personnel will instruct subjects on how to store study  drug for at -home use in case 
subjects are discharged from the hospital during the treatment peri od. 
For subjects who are discharged before Day  3, no intensive PK sampling will be performed.
7. TREA TMENT COMPLIA NCE
Missed doses (including those lost resulting from vomiting) will be recorded in the source 
documents and the eCRF , and re-dosed if the missed dose is discovered <6 hours past the 
scheduled dosing time. If the missed dose is >6 hours past the scheduled dosing time, the missed 
dose should be skipped, and the next dos e should be taken as scheduled.
Subjects who are discharged during the treatment period, will receive study  medication for at-
home use.Compliance will be assessed at each visit by counting study  drug dispensed and study 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
44
Approved , Date: 19 September 2016drug returned. Discrepancies will be discussed with the subject and recorded in the source 
documents and the e CRF .
If a subject’s study  drug intake is not according to the protocol, the investigator will take the 
necessary  measures to ensure future adherence to the protocol.
8. PRESTUDY AND CONCOMI TANT THERAPY
Prestudy  therapies administered up to 7daysbefore the first dose of study  drug must be recorded 
at screening.
Concomitant therapies must be recorded throughout the study  beginning with the first dose of 
study  drug until the Final Study  Visit/Safety  Follow -up Visit . Concomitant therapies should also 
be recorded beyond the Final Study  Visit/Safet y Follow -up Visit only in conjunction with SAEs
that meet the criteria outlined in Section 12.3.2 ,Serious Adverse Events.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special 
diets, exercise regimens) different from the study drug must be recorded in the eCRF. Recorded 
information will include a description of the type of the drug, treatment period, dosing regimen, 
route of administration, and its indication.
The following pre -study  and concomitant therapies are disallowed:
1.More than 3 doses of the influenza antiviral medication oseltamivir, zanamivir, or peramivir 
since the start of the influenza symptoms.
2. Ribavirin within 6 months of screening until the end of the study .
3.Substrates of OATP1B1 and/or OATP1B3, including atrasentan, bosentan, ezetimibe, 
glyburide, irinotecan, repaglinide, rifampin, telmisartan, valsartan, and olmesartan, from 
Day 1 through the last dose of study drug . Statins (ie, HMG CoA reductase inhibitors) 
may be continued, but subjects should be cautioned and observed for potential statin -related 
toxicity . 
4.An investigational agent (small molecule) or investigational vaccine within 30days, or an 
investigational biological product within 3months or 5 half-lives (whichever is longer) 
prior to the first dose of study drug until the end of the study .
Before the start of the study , the acute (< 7 days) use of corticosteroids (inhaled or systemic) is 
permitted; chronic ( ≥14 day s) use of corticosteroids is permitted for prednisone doses ≤ 15mg (or 
equivalent).
All use of antipy retic and anti-inflammatory  agents for the treatment of influenza symptoms will 
be recorded. Subjects should restrict their use of anti-pyretic/anti -inflammatory  medications only  
to acetaminophen (paracetamol) during the conduct of the study , and only when necessary  to 
control significant influenza symptoms. The dose is not recommended to exceed 500 mg 3 times 
a day, and should preferably  be administered immediately  after the assessment of influenza 
symptoms. The use of other medications for the relief of influenza symptoms is strongly 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
45
Approved , Date: 19 September 2016discouraged. If the subject has an allergy  or intolerance to acetaminophen (paracetamol), the 
investigator should recommend ibuprofen (at the lowest effective dose, but no more than 400 mg 
3 times a day) as a substitute medication for the relief of influenza symptoms. If ibuprofen 
cannot be used, the investigator may  use his/her discretion in the choice of agent. 
For any concomitant therap y given as a treatment for a new condition or a worsening of an 
existing condition, the condition must be documented in the Adverse Event Section of the eC RF.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The TIME AND EVENTS SCHEDUL Esummarizes the frequency  and timing of PKsampling ,
safet y, efficacy , biomarker, and patient -reported outcome ( PRO )measurements applicable to this 
study .
All visit-specific PRO assessments should be conducted /completed before any tests, procedures, 
or other consultations for that visit to prevent influencing subject perceptions.
If multiple assessments are scheduled for the same time point, it is recommended that procedures 
be performed in the following sequence: ECG, vital signs, blood sampling . Urine and blood 
collections for PKand PD assessments should be kept as close to the specified time as possible. 
Other measurements may be done earlier than specified time points if needed. Actual dates and 
times of assessments will be reco rded in the source documents and eCRF.
Additional serum or urine pregnancy  tests may beperformed, as determined necessary  by the 
investigator or required bylocal regulation, to establish the absence of pregnancy  at any time 
during the subject's participation in the study .
The total blood volume to be collected from each subject will b e approximately 125mL.
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.
9.1.2. Screening Phase
In order to start treatment as soon as possible after the start of the influenza infection, screening 
will occur on Day 1, before randomization and the first administration of study  drug. Note:
Day 1 encompasses signing of the ICF approximately  + 24 hours, and can be split over 2 
calendar days if needed. Depending on the time of hospital admission and the timing of 
screening/baseline assessments, eligibility  may only be established on the next calendar day, in 
which case the first study  drug intake will be on that day, immediately  after establishing 
eligibility .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
46
Approved , Date: 19 September 2016At the screening visit, after signing of the ICF (see Section 16.2.3 , Informed Consent for more 
details), the overall eligibility  of the subject to participate in the study  will be assessed and 
documented in the eCRF. Subjects who successfully  meet all inclusi on criteria and none of the 
exclusion criteria will be eligible for participation in the study .
The subject’s characteristics, demographic data, medical and surgical history , and prestudy  and 
concomitant medication will be recorded. A PCR -based rapid molec ular diagnostic assay  capable 
of distinguishing between influenza types A and B will be carried out as part of the screening 
procedures. Only those subjects testing positive for influenza A will be considered for 
enrollment. A physical examination (includi ng height and body  weight measurements if not 
alread y available and if practicall y feasible ) will be conducted. Aurine pregnancy  test will be 
performed for all female subjects of childbearing potential.
Subjects will be requested to complete ePRO assessm ents (Flu-iiQTM,Flu-PRO and additional 
daily  diary items ) to assess influenza -related signs and symptoms and the impact of influenza on 
the conduct of dail y activities (see Section 9.4.1 for more details).
Blood sample s (for hematology , biochemistry , blood coagulation parameter s, drug 
concentrations , and biomarker analysis)and a urine sample (for urinal ysis)will be taken. Where 
local regulations permit, an optional blood sample may be collected at baseline for host DNA 
genot yping. Nasal MT swab swill be obtained. Vital signs (systolic blood pressure [SBP], 
diastolic blood pressure [DBP], pulse rate, respiratory  rate, body  temperature , and level of 
consciousness) and blood oxygen saturation will be measured, and a 12-lead ECG will be 
performed .A historical ECG within 1 day before signing of the ICF can be used in lieu ofthe 
baseline ECG requirement .
9.1.3. Double -Blind Treatment Phase
Subjects who meet all eligibility  criteria will be randomized in a 2:1 ratio to receive 1of the 
following 2 treatments:
JNJ-63623872 600 mg bid + oseltamivir 75 mg bid on Day s 1 through 7; OR
JNJ-63623872 p lacebo bid + oseltamivir 75 mg bid on Day s 1 through 7.
Note: For subjects who receive only  1 dose on Day  1(evening) , dosing should continue until the 
morning of Day  8 so that all subjects receive 14 doses in total.
Oseltamivir dose should be reduced to 30 mg bid for subjects with an eGFR >30and 
≤60mL/min/1.73 m²according to the MDRD equation . Dose can be adjusted from 30 mg to 
75 mg and vice versa during the course of treatment based on the eGFR value.
Subjects will undergo intensive PK sampling and sparse PK sampling at the time point s specified 
in the TIME AND EVENTS SCHEDUL E.
Throughout the treatment period, ePRO assessments will be completed before any other 
assessments for a specific visit; asymptom -directed physical examination, blood sampling (for 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
47
Approved , Date: 19 September 2016hematology , biochemistry , blood coagulation parameters, drug concentrations, and biomarker 
analysis), urine sampling (for urinal ysis), and a urine pregnancy  test (for females of childbearing 
potent ial) will be performed ; nasal MT swab swill be obtained ; vital signs and blood oxygen 
saturation will be measured ;and a 12-lead ECG will be performed at the time points specified in 
the TI ME AND EVENTS SCHEDUL E.
Subjects should be observed/interviewed for any AEs (including complications of influenza ), 
concomitant medication will be reviewed, and AEs and concomitant medication will be 
recorded.
Subjects, who are discharged during the treatment phase, will receive study  medication for 
at-home use. Local PCR -based rapid molecular diagnostic testing will be carried out on the day 
of discharge and, if possible, on the day  before.
Subjects who prematurely  discont inue study  drug treatment for any  reason (except withdrawal of 
consent) will be asked to continue with their remaining study  visits and assessment schedule, or, 
at a minimum, to return to the site for a safet y follow -up visit. Subjects who withdraw consent
during the treatment phase will be offered an optional safet y follow -up visit. If the subject 
discontinues treatment due to an AE or other medical reason, efforts will be made by the 
investigator to continue following up with the subject at regular interv als until the AE normalizes 
or returns to the subject’s baseline condition. The sponsor and the investigator will agree on an 
acceptable individual follow -up schedule for these subjects. Under this protocol, there will be no 
option to extend study  treatmen t for subjects who remain hospitalized and symptomatic at the 
end of the 7 -day treatment period. A subject will be considered to h ave completed treatment after 
7-day therapy . It is up to the investigator’s discretion to administer standard of care to 
hospitalized patients who in their opinion need additional therapy , outside of this protocol.
9.1.4. Posttreatment Phase (Follow -Up)
Subjects who prematurely discontinue the study  for any  reason ( including withdrawal of consent) 
will be offered an optional safety follow -up visit. In case of ongoing AEs, efforts will be made 
by the investigator to continue following up with the subject at regular intervals until the AE 
normalizes or returns to the subject’s baseline condition. 
The procedures to be completed during the follow -up phase are listed in the TIME AND 
EVENTS SCHEDULE .
9.1.5. After discharge from the hospital
In case subjects are discharged from the hospital during the study , the remainder of the study 
visits should be carried out as outpatient visits (preferabl y on-site or, if not feasible, at the 
subject’s home) or by telephone follow -up as indicated in the TIME AND EVENTS 
SCHEDUL E. Every  effort should be made to perform all of the assessments as outlined in the 
TIME AND EVENTS SCHEDUL E(either o n-site or at the subject’s home) if practicall y 
feasible. Telephone contact will be made on Days 2-4and 6-7toensure compliance with study 
drug intake, remind subjects to complete the ePRO assessments (and to perform nasal self-
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
48
Approved , Date: 19 September 2016swabbing if applicable) , and to inquire about possible AEs and concomitant medication use. If 
the information on AEs and concomitant medications is obtained via telephone contact, written 
documentation of the communication must be available for review in the source documents. If 
the subject has died, the date and cause of death will be collected and documented in the eCRF.
9.2. Pharmacokinetics
9.2.1. Evaluations
Venous blood samples of approximately  1-2mL will be collected for measurement of plasma 
concentrations of JNJ-63623872 (and, at the sponsor's discretion, for oseltamivir and oseltamivir 
carbox ylate concentrations) at the time points specified in the TIME AND EVENTS 
SCHEDUL E, and processed, handled and identified according to the laboratory  manual, which 
will be provided before the start of the study . The exact dates and times of blood sampling and 
study  drug intake must be recorded in the eCRF and/or laboratory  requisition form. Measurement
of plasma concentrations of oseltamivir and oseltamivir carbox ylatemay be done at the 
sponsor’s discretion.
All hospitalized subjects will undergo intensive PK sampling onDay 3, at 8 different time 
points within the dosing interval. The first sample should be collected before (preferabl y 
immediately  prior to) study  drug intake (≤1 hour prior to the morning dose). Samples 2 to 8 
should be collected at 1, 2, 4, 6, 8, 10, and12 hours after the morning dose (and prior to the 
evening dose) . For subjects who are discharged before Day 3, no intensive PK sampling will be 
performed.
During hospitalization, sparse PK sampling will be performed as follows:
On Day 1: predose ( ≤1 hour prior to study  drugintake ), between 1.5 and 6hours, and 
12hours after that same study  drug intake (and prior to the next study  drug intake ). For 
subjects who start dosing in the morning of Day  1, a trough sample will be taken predose 
on Day  2 (≤1 hour p rior to the morning dose).
On Day 2 and Days 4-7: predose ( ≤1 hour prior to dosing ) and between 1.5 and 6hours 
after the morning or evening dose (whichever is the most convenient).
After discharge, sparse PK sampling will be performed as follows (if practically  feasible) :
On Day  5: at an y time during the visit .
On Day  8: at an y time during the visit.
As long as subjects are hospitalized, t he following times need to be recorded in the eCRF:
Date and time of all study  drug intakes,
Date and time of PK sampling, 
Date and start and stop times of food intake for all study  drug intake s(if applicable) . 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
49
Approved , Date: 19 September 2016After discharge, the above -mentioned dates and times will only  need to be recorded on days with 
PK sampling.
For details on stud y drug intake, see Section 6.
9.2.2. Analytical Procedures
Plasma samples will be analy zed to determine concentrations of JNJ -63623872 using a validated, 
specifi c, and sensitive (LC-MS/MS ) method by or under the supervision of the sponsor. 
Measurement of plasma concentrations of oseltamivir and oseltamivir carbox ylatemay be done 
at the sponsor’s discretion.
If required, some plasma samples may be analy zed to docu ment the presence of circulating 
metabolites using a qualified research method. In addition, plasma PK samples may  be stored for 
future analy sis of oseltamivir and oseltamivir carbox ylate,protein binding ,and metabolite 
profile.
9.2.3. Pharmacokinetic Parameters
Based on the individual plasma concentration- time data, using the actual dose taken and the 
actual sampling times, PK parameters and exposure information of JNJ-63623872 will be 
derived using non- compartmental anal ysis.
For JNJ -63623872
On Day  3: Ctrough, Cmin ,Cmax, tmax, and AUC 12h
Additional PK parameters may  be included if deemed appropriate. Actual sampling times will be 
checked for major aberrations. In case a major aberration occurs for an actual sampling time of 
>20.00% deviation from the schedu led time, this plasma concentration will be excluded from 
descriptive statistics in the plasma concentration table.
9.2.4. Pharmacokinetic Endpoints
The PK endpoint, being the primary  endpoint of this study  islisted in Section 11.3.
9.2.5. Pharmacokinetic and Pharmacokinetic /Pharmacodynamic 
Evaluations 
A population PKand PK/PD analysisof plasma concentration -time data of JNJ-63623872 will 
be performed using the nonlinear mixed -effects modeling approach. A more detailed description 
of the methodology  to be followed will be given in the clinical pharmacology  analysis plan 
(CPAP). Listings of JNJ-63623872 plasma concentration data from this study  will be reported in 
the bioanaly tical report for this study . Results of the population PK/PD analysis will be reported 
in a stand- alone document.
9.3. Safety  Evaluations
Details regarding the IDMC are provided in Section 11.8.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
50
Approved , Date: 19 September 2016Safety  and tolerability  will be evaluated throughout the study  from signing of the ICFonwards 
until the last study -related activity .
Any clinically  relevant changes occurr ing during the study  must be recorded in the Adverse 
Event section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached. 
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the TIME AND EVENTS SCHEDULE :
9.3.1. Adverse Events
Adverse events (including influenza complications) will be reported by the subject (or, when 
appropriate, by a caregiver, surrogate, or the subject's legall y acceptable representative) for the 
duration of the study . Adverse events will be followed by the investigator as specified in 
Section 12, Adverse Event Reporting.
Special attention will be paid to those subjects who discontinue the study  for an AE, or who 
experience an AE of at least grade 3, or an SAE. 
9.3.2. Clinical Laboratory  Tests
Blood samples for serum chemistry  and hematology  and a random urine sample for urinaly sis 
will be collected. The investigator must review the laboratory  report, document this review, and 
record any  clinically  relevant changes occurring during the study  in the Adverse Event section of 
the eCRF. The laboratory reports must be filed with the source documents.
Iffeasible, s afety  blood samples will be collected after fasting for at least 10 hours.
In case a grade 3or grade 4laboratory  abnormality  occurs, a confirmatory  test may be 
performed , preferabl y within 48 hours but no later than 72 hours after the results have become 
available.
The following tests will be performed b y the central laboratory:
Hematology  Panel
-hemoglobin -WBC differential
-hematocrit *neutrophils
-red blood cell (RBC) count *lymphocy tes
-RBC parameters *monocy tes
*mean corpuscular hemoglobin (MCH) *eosinophils
*MCH concentration *basophils
*mean corpuscular volume -platelet count
-white blood cell (WBC) count
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
51
Approved , Date: 19 September 2016A WBC evaluation may include any abnormal cells, which will then be reported by the 
laboratory . Any RBC evaluation may include abnormalities in the RBC count and/or RBC 
parameters and/or RBC morphology , which will then be reported by  the laboratory .
Serum Chemistry  Panel
-sodium -uric acid
-potassium -eGFR
-chloride -calcium
-bicarbonate -calcium (corrected for albumin)
-blood urea nitrogen (BUN) -phosphate
-creatinine -serum albumin
-glucose -total protein
-AST -total cholesterol
-ALT -high-density  lipoprotein cholesterol
-GGT -low-densit y lipoprotein cholesterol
-total, direct, and indirect bilirubin -triglycerides
-ALP -magnesium
-CPK -lipase
-lactic acid deh ydrogenase (LDH) -pancreatic amy lase
-α1-acid gl ycoprotein
Urinaly sis
Dipstick Sediment (if dipstick result is
-specific gravit y abnormal)
-pH -RBCs
-glucose -WBCs
-protein -epithelial cells
-blood -crystals
-ketones -casts
-bilirubin -bacteria
-urobilinogen
-nitrite
-leukocy te esterase
In case the dipstick shows 4+ (or >1.0%) proteinuria, a confirmatory  test must be performed 
preferabl y within 48 hours but no later than 72 hours after the results have become available. If 
dipstick result is abnormal, flow cytometry  or microscop y will be used to measure sediment. In 
case of discordance between the dipstick results and the flow cytometric results, the sediment 
will be examined microscopicall y.
Dipstick and flow cytometric analysis of the urine samples will be performed in parallel, ie, in 
the same sample at the same time.
At screening , at Day 5,and at the Final Study  Visit/Safet y Follow -up Visit, a urine 
pregnancy  testwill be performed for female subjects of childbearing potential only .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
52
Approved , Date: 19 September 2016At screening, follicle -stimulating hormone (FSH)will be tested for female subjects who are 
amenorrheic for 12 months or less.
At screening, hepatitis A, B, and C serologic testing will be performed.
At screening and at the time points indicated in the TIME AND EVENTS SCHEDUL E, 
determination of the following coagulation parameters will be performed: prothrombin time 
(PT), activated partial thromboplastin time (aPTT), and fibrinogen. International normalized 
ratio (INR) will be calculated.
9.3.3. Electrocardiogram
During the collection of ECGs, subjects should be in a quiet setting without distractions (eg, 
television, cell phones). Subjects should rest in a supine position for at least 5minutes before 
ECG collection and should refrain from talking or moving arms or legs. If blood sampling or 
vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG, vital signs, blood draw. A historical ECG 
within 1 day  before signing of the ICF can be used in lieu of the baseline ECG requirement .
Twelve -lead ECGs will be recorded so that the different ECG intervals (PR, QRS, and QT) and 
heart rate will be measured. The QT intervals will be corrected for heart rate according to 
Bazett’s (QTcB) and Fridericia’s (QTcF) QT correction.5,10
Clinically  relevant abnormalities occurring during the study  should be recorded in the Adverse 
Event Section of the eCRF.
9.3.4. Vital Signs (temperature, pulse/heart rate, respiratory  rate, blood 
pressure , blood oxygen saturation , level of consciousness)
Vital signs including temperature, pulse/heart rate, respiratory  rate, blood pressure ,peripher al 
arterial blood oxygenation , and level of consciousness will be assessed once daily  at screening 
and at the Final Study  Visit/Safety  Follow -up Visit . Vital signs will be assessed at least 3 times 
daily  until the subject is discharged from the hospital or until Day 14 (whichever comes first) : in 
the morning (prior to study  drug intake if applicable) , approximately  half-way in the middle of 
the day, and in the evening (prior to study drug intake if applicable) .If the subject is dischar ged 
from the hospital, vital signs will be measured once daily  on Day 5 and Day 10,if practicall y 
feasible .In case, per standard practice, vital signs are measured more frequently  than required 
per protocol, these additional measurements will also be recorded in the eCRF . 
Temperature will be measured orally .
Blood oxygen saturation will be measured using standard pulse oximeter . Subjects should have 
nail polish removed and should be encouraged to sit still during the measurements.
Blood pressure, pulse/heart rate, and respiratory  rate measurements should be preceded by at 
least 5 minutes of rest in the supine position in a quiet setting without distractions (eg, television, 
cell phones).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
53
Approved , Date: 19 September 2016Blood pressure , pulse/heart rate, respiratory  rate, and temperature measurements will be assessed 
with a completel y automated device. Manual techniques will be used only  if an automated device 
is not available.
The level of consciousness will be measured according to the AVPU scale (alert, voice, pain, 
unresponsive).8Alert: The patient is fully  awake (although not necessaril y oriented). This patient 
will have spontaneousl y open eyes, will respond to voice (although may be confused), and will 
have bodily  motor function. Voice: The patient makes some kind of response when you talk to 
them, which could be in any  of the 3component measures of eyes, voice ,or motor .The response 
could be as little as a grunt, moan, or slight move of a limb. Pain: The patient makes a response 
on any of the 3component measures on the application of pain stimulus, such as a central pain 
stimulus (sternal rub)or a peripheral stimulus (squeezing the fingers ). Unresponsive: Someti mes 
seen noted as 'Unconscious'; this outcome is recorded if the patient does not give any eye, voice 
or motor response to voice or pain. The National Early Warning Score (NEWS) will be derived 
based on vital signs and AVPU scale at baseline and during hospitalization.12
Clinically  relevant abnormalities (as defined in Attachment 7) occurring during the study  should 
be recorded in the Adverse Event Section of the eCRF.
9.3.5. Physical Examination 
To evaluate the subject’s eligibility , a physical examination (including height and body  weight 
measurement if not already  available and ifpractically feasible ) will be performed at screening. 
In addition, a symptom -directed physical examination will be performed at thetime points 
provided in the TIME AND EVENTS SCHEDULE .
A physical examination includes a review of the following systems: head/neck/th yroid; 
eyes/ears/nose/throat (EENT); respiratory ; cardiovascular; lymph nodes; abdomen; skin; 
musculoskeletal; and neurological. Breast, anorectal, and genital examinations will be performed 
when medicall y indicated.
To obtain the actual body  weight, subjects must be weighed lightl y clothed. The height should be 
measured barefoot.
Any clinically relevant changes occurring during the study  must be recorded in the Adverse 
Event Section of the eCRF.
9.3.6. Specific Toxicities
Subjects reporting allergic reactions, AST/AL T elevations, clinical hepatitis, renal 
complications, nausea, or diarrhea, and other laboratory parameter changes should be followed 
until resolution of the AE or toxicity  and necessary standard management should be undertaken.
Refer to Section 10.2 for study  drug discontinuation criteria.
Acute Systemic Allergic Reaction
Cetirizine, levocetirizine, topical corticosteroids or antipruritic agents may  be prescribed.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
54
Approved , Date: 19 September 2016Subjects should be advised to contact the investigator immediately  if there is any worsening of 
the acute s ystemic allergic reaction.
Subjects will be treated as clinically  appropriate.
AST and ALT Elevation
Subjects should be followed until resolution (return to baseline) or stabilization of AST/AL T 
elevation (to be agreed upon with the sponsor).
Clinical Hepatitis
Subjects taking the study drugs should be monitored for the development of signs and sy mptoms 
of hepatitis which include fatigue, malaise, anorexia, nausea, dark urine and clay-colored stools, 
bilirubinuria, jaundice, liver tenderness, or hepatomegal y, with or without initially  abnormal 
serum transaminase levels.
Subjects with these signs and symptoms must seek medical attention immediately  and have 
hepatic parameters assessed. Relevant markers of viral hepatitis should als o be assessed.
Renal Complications
If renal complications develop, subjects should be closely  monitored for disturbances in serum 
creatinine and for abnormalities in urine analysis (eg, proteinuria). Additional investigations can 
be performed at the i nvest igator´s discretion. Subjects must be treated as clinically  appropriate.
Nausea (with or without Vomiting)
Subjects may  be treated as needed with antiemetics given orall y or rectally .The date and time of 
this AE should be recorded.
Diarrhea
Loperamide can be administered.
Other Laboratory Parameter Changes
If one (or more) of the following changes occurs ,the subject should discontinue study  drug and 
should be followed until resolution (return to baseline) or stabilization of change (to be agreed 
upon with the sponsor) . The sponsor should be informed even if the change occurs outside of the 
treatment period (but before the end of the study ).
Liver enzy mes -screening/ baseline
AST or ALT enzy me activity  increases ≥5 xULN
Direct bilirubin increases ≥2x ULN
GGT and/or ALP enzyme activity increases ≥3xULN
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
55
Approved , Date: 19 September 2016Liver enzy mes -during treatment
AST or ALT enzy me activity  increases ≥5 x UL Nif the baseline value is normal
AST or ALT enzy me activity  increases ≥5 x baseline if the baseline value is >ULN
ALTenzy me ac tivity increases >15x UL N
ALT enzy me activity increases >3 x UL Nand total bilirubin increases >2 x ULN
Confirmed a bsolute neutrophil count < 500/mm3
Hemoglobin <9 g/dL (female), <10.5 g/L (male)
9.4. Efficacy  
9.4.1. Evaluations
9.4.1.1. Patient -reported Outcomes
Subjects should complete the PRO assessments (Flu-iiQTM,Flu-PRO and additional daily  diary 
items) in their native language or if there is no version available in their native language, a 
version in a language in which the subject is fluent and literate. It is preferable that subjects are 
able to read and write to complete the assessments by  themselves. If a subject is unable to read or 
has visual or other phy sical limitations that make it difficult to read or complete the assessments, 
trained study  personnel may  read the questions and responses aloud exactly  as they  appear on the 
assessment and record the subject’s responses during the hospitalization phase. Once the subject 
is discharged from the hospital, if the subject is unable to complete the PRO assessment una ided, 
a caregiver can read the questions and responses verbatim and record the subject's responses for 
the subject.
Study  personnel will instruct subjects how to self-administer the PRO tool and will record in the 
eCRF whether the PRO assessments were performed during the study visit. If subjects will 
require assistance recording their responses post-hospital discharge, study  personnel will instruct 
the caregiver how to administer the PRO assessments.
Subjects will complete the PRO assessments electronicall y on a touch screen computer (ePRO 
device) provided for this study . The subject should be provided a quiet place to complete the 
PRO assessments, and instructed how to complete the PRO assessment on the ePRO device . 
When deciding which answer to report, subjects should notreceive any help from anyone 
accompan ying them (such as family  members and friends) or study  personnel; the responses 
should reflect the subject’s interpretation and response.
Subjects’ responses to the PRO questionnaires will not be repo rted as AEs or SAEs .
Influenza Symptom Score (Flu -iiQTMModule 1)
Subjects will be asked to assess influenza -related signs and symptoms and other patient -reported 
outcomes and associated severit y twice daily  (preferabl y in the morning and in the evening) from 
study  entry (Baseline, Day 1) through Day 14, and once daily (preferably  in the evening) from 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
56
Approved , Date: 19 September 2016Day 15 through the Final Study  Visit/Safet y Follow -up Visit, using the Flu-iiQTMinfluenza 
intensity  and impact questionnaire (see Attachment 3) on an ePRO device.
Assessment of influenza symptoms will be recorded by the subjects or the site staff/caregiver if 
the subject requires assistance on the ePRO device and analyzed as an efficacy  measure of 
treatment. Resolution of influenza symptoms will be the time since the start of treatment of the 
first of 2evaluations (over 24hours) in which all symptom scores for each of the 2assessments 
are none or mild for all 7 primary  influenza symptoms (cough, sore throat, headache, nasal 
stuffiness, feverishness or chills, muscle or joint pain, and fatigue).
Impact of Influenza (Flu -iiQTMModules 2, 3, 4)
The impact of influenza on conduct of daily activities will be assessed in Module 2 of the 
Flu-iiQTM(seeAttachment 3), scored on a 4 -point scale, as above, for each of 6 activities. Scores
will be assessed twice daily , at the same times as when the symptom scale evaluation is 
performed, from study  entry (Baseline, Day 1) through Day 14, and once daily  from Day 15
through the Final Study Visit/Safety  Follow -up Visit. Assessments along with the additional 
daily  diary items (see Attachment 4) will be recorded on the ePRO device. Time to resumption 
of usual activities is the time at which all scores are reported as “no difficulty ”.
Flu-PRO
The incidence and severity  of symptoms (individual and composite) will be evaluated using the 
Flu-PRO questionnaire (see Attachment 5). Subjects will be asked to complete this questionnaire 
and additional daily  diary items (see Attachment 6) on an ePRO device once daily (preferabl y in 
the evening) from study  entry (Baseline, Day 1) through the Final Study  Visit/Safety  Follow -up 
Visit.
9.4.1.2. Viral Kinetics (Nasal MT Swabs)
Influenza viral titer will be determined and quantified in nasal MT swab samples taken at 
scheduled times throughout the study as indicated in the TIME AND EVENTS SCHEDUL E. 
Nasal MT swabs will be analyzed using qRT-PCR and/orviral culture , and PCR- based rapid 
molecular testing. Influenza A subty pe will be determined from the baseline sample.
When subjects are discharged from the hospital and still positive for influenza A virus , they are 
encouraged to continue self- swabbing at home if practicall y feasible.
Details about the nasal MT (self-) swab sample collection, processing, and shipping will be 
provided i n the laboratory manual or other instruction document s.
The nasal MT swabs for central testing should be obtained from the left and the right nostril sand 
pooled into the same collection tube. Nasal MT (self)swabs for local PCR -based rapid molecular 
testin g should be obtained from the left and the right nostril s(from both nostrils if feasible, but 
from only one nostril otherwise) and pooled into the same collection tube. Sampling should be 
done at approximately  the same time when required . The investigator should designate a limited 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
57
Approved , Date: 19 September 2016number of trained study  site personnel to collect the nasal MT swabs for the sake of consistency , 
and to train subjects on how to collect self-swabs if applicable.
9.4.2. Efficacy  Endpoints
The efficacy  endpoints, being the secondary  endpoints of this study  are listed in Section 11.6.
9.5. Resistance Evaluations
9.5.1.1. Viral Sequencing
Samples collected as described in Section 9.4.1.2 will also be used for sequence analy sis of the 
PB2 region of the influenza virus pol ymerase and theneuraminidase gene at the time points
specified in the TIME AND EVENTS SCHEDULE . Exploratory  sequencing of other regions of 
the influenza virus genome may also be perf ormed.
9.5.1.2. Phenotyping
Nasal MT swabs will be used for the analysis of phenoty pic resistance against JNJ -63623872 and 
other antivirals at the time points specified in the TIME AND EVENTS SCHEDULE.
Details about sample collection, processing, and shipping will be provided in the laboratory 
manual.
9.6. Biomarkers 
Two blood samples will be collected at the time points specified in the TIME AND EVENTS 
SCHEDUL Efor the exploration of blood biomarkers (eg, host RNA, proteins including serum 
cytokines) on the premise that these markers may play a role in the blood concentrations , 
treatment response, or safet y of JNJ-63623872 or oseltamivir, or the status and change of the 
influenza virus related disease. Where local regulations permit, an optional blood sample may be 
collected for host DNA genoty ping. 
In addition, nasal MT swabs collected for other testing may be used for biomarker analyses if 
available.
Analy ses of biomarkers (including DNA) may be conducted at the sponsor’s discretion and 
reported separatel y from this study .
Blood samples for pharmacogenomic evaluations will preferably be collected at the baseline 
visit. However, if necessary  eg, in case of a technical failure, they may be collected at a later 
time point without constituting a protocol deviation.
9.7. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate 
amount (1 mL) of serosanguineous fluid slightly  greater than the dead space volume of the lock 
will be removed from the cannula and discarded before each blood sample is taken. After blood 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
58
Approved , Date: 19 September 2016sample collection, the cannula will be flushed with 0.9% sodium chloride, United States 
Pharmacopeia (USP) (or equivalent) sodium heparin of 10 U/mL and charged with a volume 
equal to the dead sp ace volume of the lock.
Refer to the TIME AND EVENTS SCHEDULE for the timing and frequency  of all sample 
collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the study  if he or she has completed all 
assessments of the Final Study  Visit .
10.2. Discontinuation of Study Treatment
If a subject's study  treatment must be discontin ued before the end of the treatment regimen, this 
will not result in automatic withdrawal of the subject from the stud y.
A subject's study  treatment should bediscontinue d if:
The investigator believes that for safet y reasons (eg,AE) it is in the best interest of the 
subject to discontinue study treatment
The subject becomes pregnant
The subject undergoes mechanical ventilation
The subject requires peritoneal dial ysis, hemodialysis, or hemofiltration
The subject has an eGFR ≤30 mL /min/1.73 m² according to the MDRD equation
The subject experiences any of the laboratory  abnormalities as specified in Section 9.3.6 , 
Specific Toxicities.
If a subject prematurel y discontinues study  treatment, follow -up assessments should be obtained 
and scheduled assessments should be continued. If a subject drops out due to withdrawal of 
consent, he or she will be offered an optional Safety Fol low-up Visit .
10.3. Withdrawal From the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
59
Approved , Date: 19 September 2016If a subject is lost to follow -up, every reasonable effort must be made by  the study  site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. The measures 
taken to follow up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study  drug assigned to the withdrawn 
subject may not be assigned to another subject. Subjects who withdraw will not be replaced. If a 
subject withdraws from the study  before the end of the treatment or the follow -up phase, he or 
she will be offered an optional Safety  Follow -up Visit.
A subject who withdraws from the study  will have the following options regarding the optional 
research sample:
The collected sample will be retained and used in accordance with the subject's original 
separate ICF for optional research samples.
The subject may withdraw consent for optional research sample, in which case the sample 
will be destroy ed and no further testing will take place. To initiate the sample destruction 
process, the investigator must notify  the sponsor study  site contact of withdrawal of consent 
for the optional research samples and to request sample destruction. The sponsor study  site 
contact will, in turn, contact the biomarker representative to execute sample destruction. If 
requeste d, the investigator will receive written confirmation from the sponsor that the 
sample has been destro yed.
Withdrawal From the Use of Sample s in Future Research
The subject may withdraw consent for use of sample sfor research ( see Section 16.2.5 , Long -
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retention
for research are presented in the main I CF.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor orunder the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan.
11.1. Subject Information
For all subjects who receive at least 1dose of study  drug descriptive statistics will be provided.
All demographic characteristics (eg, age, race, height, body  weight, body  mass index [ BMI]) and 
other initial subject characteristics (physical examination, medical and surgical history , 
concomitant diseases, etc.) will be tabulated and analyzed descriptivel y.
11.2. Sample Size Determination
Up to 90 subjects in total will be enrolled in this study . An effort will be made to include at least 
24subjects for each cohort ,with the total of subjects allowed to be recruited across both cohorts . 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
60
Approved , Date: 19 September 2016It is anticipated that it is feasible to recruit at least 60 subjects, which would lead to an acceptable 
precision for the primary objective.
For the primary  objective of evaluating the PKof JNJ-63623 872 across age cohorts the PK 
parameters considered of major importance are Cmin, C max, and AUC 12h. As there are no data 
available where Day 3 has been part of extensive PK sampling on the 600 mg bid dose, the 
variability  on days with available data are presented in Table 2. Based on those data a between-
subjects CVof 60% was assumed as a reasonab ly conservative estimate for the current study .
Table 2: Variability for Key Pharm acokinetic Param eters for JNJ -63623872 600 m g bid (Between -
subjects %CV)
Time point N Cmin Cmax AUC 12h
Day 1 12 NA 65 56
Day 5 18 77 57 61
Day 5* 18 48 57 46
Day 10 12 56 44 43
Note: Based on study 63623872FLZ1001. 
*JNJ-63623872 600 mg bid + oseltamivir 75 mg bid. 
NA: Not applicable.
For age cohorts it was assumed that the number of hospitalizations would be about equal for 
elderl y and non-elderl y adults. In case 60 subjects are enrolled, there are 40 subjects on active 
treatment and it is assumed that at least 16subjects are on active treatment in each cohort ).For 
the comparison of PK parameters of the cohort of elderl yadults (test) vs. non-elderly  adults 
(reference) with PK data in a 16 to 24 ratio and a between -subject coefficient of variation (CV) 
of 60%, the 90% confidence interval (CI) of the geometric mean ratio (GMR) for Cminwould be 
predicted to have a half-width of 35%, indicating that we can be 90% confident that the true 
GMR is in the interval observed GMR/1. 35 to 1.35*GMR. If 90 subjects were enrolled with 60
on active treatment in a 24 to 36 ratio, the predicted half -width would be 28%.
The precision was expressed as the half -width of the 90% confidence band around the predicted 
mean LOESS estimate (illustrated in a simulated situation presented inFigure 1, with circles as 
the individually  simulated values for C min, as a solid line the predicted values and the shaded area 
the 90% confidence band for the prediction). With the anticipated numbers of subjects, the 
average half-widths and the maximum half-width are presented in Table 3as percentages. The 
average half-width is the relative distance between the prediction and the 90% confidence band 
around that mean, averaged across the observed data points. Based on 40 to 60subjects exposed 
to JNJ-63623 872, the 90% confidence band for the planned LOESS regression was considered 
sufficiently  precise (with average half -widths less than 25%) in order to evaluate t he relationship 
between age and the major PK parameters.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
61
Approved , Date: 19 September 2016Figure 1: Example of LOESS Regression for a Sim ulated Data Set for C min(N=50)
Table 3: Precision of the LOESS Confidence B and Around the Predicti on
Cmin (CV= 60%) Number of subjects treated with JNJ -63623 872
N=40 N=50 N=60
Mean half -width* 25% 22% 20%
Maximum half -width* 46% 40% 36%
*Expressed as the ratio of the upper 90% confidence band divided by the prediction de rived from the LOESS 
regression. Expressed as a percentage, based on 10.000 simulations .
For the safet y objective of the study the sample size of 40 to 60 subjects treated with 
JNJ-63623 872 can be characterized by assessing the precisions for (potentially ) observed 
treatment -emergent AEs. For example, if no related treatment -emergent SAE is observed in a 
sample of 60 subjects exposed to JNJ-63623 872, it can be concluded with 95% confidence that 
the true incidence of related treatment -emergent SAE swill be less than 5%. Table 4presents the 
one-sided upper confidence limits for a range of numbers of treated subjects.
Table 4: Upper Confidence Li mits for any Event with a Z ero Incidence
Number of subjects treated with JNJ -63623 872
N=40 N=50 N=60
Upper confidence limit* 7.2% 5.8% 4.9%
*Upper 95% confidence limit (one -sided) using the Clopper -Pearson method
Besides characterizing the precision for excluding significant side-effects, the current study  also 
allows to assess the incidence of treatment -emergent AEs on JNJ-63623 872 vs. placebo 
treatment. Table 5presents the 95% CIs for the risk difference that may potentially  be observed. Cmin (ng/mL)
0100200300400500600700800900
Age15 20 25 30 35 40 45 50 55 60 65 70 75 80 85
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
62
Approved , Date: 19 September 2016For example, with 4 events (out of 60) vs. 1 event (out of 30) the risk difference (95% CI) would 
be 3.3% ( -19%, 26%).
Table 5: Risk Differences and Associated 95% Confidence Intervals for Potential Treatm ent-emergent 
Adverse Event Incidences 
Risk difference (95% CI) by sam ple size (active: placebo)
40:20 50:25 60:30
0% ( -28%, 28%) 0% ( -25%, 25%) 0% ( -22%, 22%)
2.5% ( -25%, 30%) 2.0% ( -23%, 27%) 1.7% ( -21%, 24%)
5.0% ( -23%, 32%) 4.0% ( -21%, 28%) 3.3% ( -19%, 26%)
7.5% ( -20%, 35%) 6.0% ( -19%, 30%) 5.0% ( -18%, 27%)
10.0% ( -18%, 37%) 8.0% ( -17%, 32%) 6.7% ( -16%, 29%)
Based on exact 95% confidence intervals. Interval width only depends on risk difference. For zero events in both 
groups the confidence interval for the risk difference is not defined.
11.3. Pharmacokinetic A nalyses
Pharmacokinetic parameters will be used to assess the exposure of JNJ-63623872 on Day 3.
Refer to Section 9.2for more details.
Primary Endpoint
PK parameters of JNJ- 63623872 (ie, C min, Cmax, and AUC 12h) established on Day  3.
Intensive Pharmacokinetic Sampling (Day 3)
All plasma concentrations below the lowest quantifiable concentration or missing data will be 
labeled as such in the concentration data presentations or SAS dataset. Concentrations below the 
lower quantifiable concentration will be treated as zero in the summary  statistics. All subjects 
and samples excluded from the anal ysis will be clearly  documented in the Clinical Study  Report.
Descriptive statistics will be calculated for plasma concentrations ofJNJ-63623872 at each 
sampling time point and for the derived plasma PK parameters. Statistics include sample size (n), 
mean, standard deviation (SD), %CV, geometric mean, median, minimum, and maximum.
For each subject treated with JNJ-63623872, JNJ-63623872 plasma concentration -time data will 
be graphically  presented. Similarly , graphs of the mean plasma concentration -time profiles and 
overlay  graphs with combined individual plasma concentration -time profiles will be produced. 
Pharmacokinetic parameters will be subjected to an exploratory  graphical analy sis in order to get 
a general overview.
Statistical analy sis will be performed for the PK-evaluable population . Elderly  adults (65 to 
≤85years) will be compared vs. non-elderl y adults (reference) to investigate the relative effect of 
age. The primary  PK parameters are Cmax, Cmin, and AUC 12h. AUC 12hwill be rejected as primary 
parameter for an age cohort if more than half of the subjects of that age cohort do not have a 
reliable value .For the primary  PK parameters, the GMR of test vs. reference will be calculated 
including the associated 90% CI.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
63
Approved , Date: 19 September 2016For the assessment of an age effect, regression techniques will be employ ed to describe and 
predict the relation between age and primary  PK parameters. As the relationship need not be 
linear across age, LOESS regression will be used that allows for a nonlinear model fit. The 
LOESS model uses smoothing based on goodness of fit criteria; recognizing that marked local 
changes are not biologically  plausible, smoothing will be restricted. In case important predictive 
covariates are identified a generalized additive model will be used to model the relation between 
age and PK parameters adjusted for covariates, including LOESS regression for age. Regre ssion 
will be performed on the logarithm of the PK parameter, with the results of the regression being 
retransformed to the original scale , including the 90% confidence band around the regression 
line.For an effect of body weight on primary  PK parameters a similar approach will be used as 
an exploratory analysis.
Special attention will be paid to the plasma concentrations and PK parameters of those subjects 
who have discontinued the study  for an AE, or who experienced an AE of at least grade 3, or an
SAE.
Sparse Pharmacokinetic Sampling
Population PK analy sis of plasma concentration -time data of JNJ-63623872 will be performed 
using nonlinear mixed -effects modeling. Data may be combined with those of other selected 
studies to support a relevant structural model. Available baseline subject characteristics 
(demographics, body  weight, laboratory  variables, genot ypes, race, etc.) will be tested as 
potential covariates affecting PK parameters. Details will be given in a population PK analy sis 
plan and the results of the population PK anal ysis will be presented in a separate report. 
A snapshot date for PK samples tobe analyzed will be defined, if required. Samples collected 
before this date will be analy zed for JNJ-63623872 and included in the population PK analysis. 
Samples collected after the snapshot date will be analy zed at a later date, and may  be included in
a population PK re -analysis when they become available after database lock.
Data will be listed for all subjects with available plasma concentrations per treatment arm. 
Subjects will be excluded from the PK analy sis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study  drug; missing information of dosing and 
sampling times; concentration data not sufficient for PK parameter calculation).
All concentrations below the lowest quantifiable concentration or mis sing data will be labeled as 
such in the concentration database. All subjects and samples excluded from the analysis will be 
clearl y documented in the study report.
For each treatment arm, descriptive statistics, including sample size (n), arithmetic mean, SD, 
%CV, geometric mean, median, minimum, and maximum will be calculated for all individual ly
derived PK parameters including exposure information of JNJ -63623872.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
64
Approved , Date: 19 September 201611.4. Pharmacokinetic/Pharmacody namic A nalyses
The PK/PD relationship ofJNJ-63623872 exposure (AUC 12h, C max, or Cmin) with efficacy  (ie, 
change in viral load from baseline and virologic response) and safety  (including AEs and 
laboratory  abnormalities) will be explored. Other exploratory  anal yses may  be performed.
11.5. Safety  Analyses
All safety  endpoints will be evaluated on the Safety  population, consisting of all subjects who 
received at least one dose of study  drug and will be analyzed by drug received. Safety  will be 
evaluated by means of AEs (including complications of influenza ), clinical laboratory tests, 
ECGs, vital signs, NEWS, physical examinations, pregnancy  testing, and specific toxicities . The 
safet y analysis will be done for the Safet y population and for each study  phase separatel y 
(treatment, follow -up, and the combination of both).
Adverse Events
The verbatim terms used in the eCRF by investigators to identify  AEs will be coded using the 
Medical Dictionary  for Regulatory  Activities (MedDRA). Treatment -emergent AEs are AEs 
with onset during the treatment phase or that are a consequence of a pre-existing condition that 
has worsened since baseline. All reported AEs will be included in the analysis. For each AE, the 
percentage of subjects who experience at least 1occurrence of the given event will be 
summarized by  treatment arm. In addition, comparisons between treatment arms will be provided 
if appropriate.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an AE, or who experience a severe or a 
serious AE.
Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges and markedl y 
abnormal results (specified in the Statistical Analy sis Plan) will be used in the summary  of 
laboratory  data. Descriptive statistics will be calculated for each laboratory  analyte at baseline 
and for observed values and changes from baseline at each scheduled time point. Changes from 
baseline results will be presented in pre-vs.post-treatment cross -tabulations (with classes for 
below, within, and above normal ranges). Frequency  tabulations of the abnormalities will be 
made. A listing of subjects with any laboratory results outside the reference ranges will be 
provided. A listing of subjects with any markedly  abnorm al laboratory results will also be 
provided.
The laboratory  abnormalities will be determined according to the criteria specified in the 
WHO grading table (see Attachment 1) and in accordance with the normal ranges of the clinical 
laboratory  if no gradings are available. Laboratory abnormalities will be tabulated by scheduled 
time point.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
65
Approved , Date: 19 September 2016Electrocardiogram
The effects on cardiovascular variables will be evaluated by means of descriptive statistics and 
frequency  tabulations. These tables will include observed values and changes from baseline 
values (the predose ECG will be used as baseline) to allow detection of clinically  relevant 
changes in individuals.
Electrocardiogram data will be summarized by ECG parameter . Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, 
and QTc interval using the following correction methods: QTcB, QTcF, and QT correction 
derived b y linear regressi on (QT cL).5,9
Descriptive statistics ofQTc intervals and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 milliseconds, 
>480 milliseconds, or >500 milliseconds will be summarized, as will the percentage of subjects 
with QT c interval increases from baseline >30 milliseconds or >60 milliseconds.
All important abnormalities in ECG waveform that are changes from the baseline readings will 
be reported (eg, changes in T-wave morphology  or the occurrence of U -waves ).
The percentag e of subjects with abnormalities will be tabulated by treatment arm.
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory  rate, blood pressure (systolic 
and diastolic) (supine) , arterial oxygen saturation values ,level of consciousness, and changes 
from baseline will be summarized at each scheduled time point. For oxygen saturation an 
overview will be presented for the number of subjects that require supplemental oxygen. The 
percentage of subjects with values beyond clinically  important limits will be summarized. For 
each subject ,the NEWS will be derived based on the vital sign data. The average of the NEWS 
over time will be presented by  treatment group.
Electrocardiogram data will be summarize d by vital sign param eters (temperature, pulse/heart 
rate and blood pressure [systolic and diastolic ]). Descriptive statistics will be calculated at 
baseline and for observed values and changes from baseline at each scheduled time point. 
Frequency  tabulations of the abnormalities will be made.
Physical Examination
Descriptive statistics of changes from baseline will be summarized at each scheduled time point.
Physical examination findings will be summarized at each scheduled time point. Descriptive 
statistics will be calculated at baseline and for observed values and changes from baseline at each 
scheduled time point. 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
66
Approved , Date: 19 September 201611.6. Efficacy  Analyses
The efficacy  endpoints will be analy zed on the Full Analy sis Set, consisting of all subjects who 
were randomized, treated and had a confirmed influenza A infection, and will be analyzed by 
drug received.
Descriptive statistics will be used for all efficacy endpoints and will be tabulated by treatment 
arm and b y age cohort. No formal statistical hypothesis testing will be made.
Clinical outcomes
The incidence of influenza complications will be categorized in a hierarchical fashion. The 
overall category  will consist of any  complication, consisting of the following subcategories:
bacterial pneumonia (culture confirmed where possible), 
other bacteri al superinfections,
respiratory  failure,
pulmonary  disease: asthma, chronic obstructive pulmonary  disease [COPD]),
cardiovascular and cerebrovascular disease (eg, myocardial infarction, congestive heart 
failure [CHF], arrh ythmia, stroke) ,
post-baseline ICU admission ,
all-cause mortality
The incidences on Day 28 of each (sub) category  will be analyzed using logistic regression; 
baseline characteristics that are predictive of the incidence of complications can be included 
based on goodness of fit criteria. Odds ratios and associated 95% CIs will be reported of active 
vs. control treatment.
The time to improvement of vital signs is defined as the time from first study  treatment to when 
at least 4of 5 symptoms (temperature, blood oxygen saturation, heart rate, SBP, respiration rate) 
are recovered, including normalization of temperature and blood oxygen saturation. 
Normalization is defined in Table 6. If subje ctssatisfy  these criteria at entry  they will be 
censored at that time (effectivel y they will be excluded from the analysis). The data will be 
presented using a Kaplan -Meier curve. The time to event data will be modeled using the 
accelerated failure time (if the data provide an acceptable model fit) or alternativel y a Cox 
proportional hazards model (in case the hazards are proportional). Additionally , the time to event 
data will be anal yzed using the Gehan -Wilcoxon method.
Table 6: Reso lution Criteria for Vital Signs
Assessment Resolution Criterion
Temperature ≤ 37.2 °C or ≤ 37.8 °C rectal or tympanic
Oxygen saturation ≥ 92% on room air without supplemental oxygen
Respiration rate ≤ 24/min
Heart rate ≤ 100/min
Systolic blood pressure ≥ 90 mmHg
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
67
Approved , Date: 19 September 2016Time to improvement of respiratory  status is defined as normalization of blood oxygen saturation 
and respiration rate. Analy sis performed will be analogous to the analy sis for the time to 
improvement of vital signs.
The ordinal scale consists of 6categories that are exhaustive, mutua lly exclusive ,and ordered 
(Table 7). For all patients ,the category  at Day  8 will be established as the worst category  on that 
day. For example, if someone is discharged on Day 8,the category  will be non-ICU and no 
supplemental oxygen (if there was no supplemental oxygen given on that day). The analysis will 
be performed using a proportional odds model, modeling the common odds ratio of the 
improvement on the ordinal scale of active treatment versus control. Baseline covariates that are 
predictive of the ordinal scale may be added to the model to increase the model fit. In case of 
missing data (>10%), a multiple imputation method under the missing -at-random assumption 
will be employ ed. D etails will be provided in the Statistical Analy sis Plan.
Table 7: Ordinal S cale on Day 8
Outcom e
Death
Admitted to ICU or mechanically ventilated/ECMO
Non-ICU + supplemental oxygen
Non-ICU + no supplemental oxygen
Not hospitalized, but unable to continue activity
Not hospitalized and continues activities
ECMO = extracorporeal membrane oxygenation ; ICU = Intensive Care Unit
Viral kinetics 
Measures of viral kinetics are performed for both qRT -PCR and viral culture of nasal MT swabs:
Duration of viral shedding defined as time to influenza A viral negativit y
Viral AUC calculated from baseline to Day  14 
Rate of decline of viral load
Incidence of influenza A viral negativity  by assessment
Peak viral shedding titer 
The time to influenza A viral negativity  will be determined based on nasal MT swabs: asubject 
will be considered influenza A viral negative at the time point that thefirst negative nasal MT
swab was recorded (in days). A subject will be censored at the time of the last observed non -
negative swab + 1 day. The time to influenza A viral negativity  will be summarized using a 
Kaplan -Meier curve. The accelerated failure time model will be used to compare the time to 
recovery  for JNJ-63623872 vs. control treatment; the accelerated failure time model will use a 
Weibull, log-logistic, lognormal or gamma distribution based on goodness of fit criteria. 
Additionally , the time to event data will be analy zed using the Gehan -Wilcoxon method. The 
AUC will be estimated for each treatment arm using a mixed model for repeated measurements, 
ie, the AUC will not be calculated for each subject and then analyzed, but the AUC will be 
calculated for each treatment arm using the viral data over time of each subject. This approach 
ensures an optimal approach towards missing data. The rate of decli ne in quantitative viral load 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
68
Approved , Date: 19 September 2016will be estimated through a pre-specified linear mixed model. The incidence of viral negativity 
will be analy zed using logistic regression. For the peak viral shedding titer a GMR will be 
derived using a general linear model. For each analysis the difference between the treatment 
arms will be presented including the associated 95% CI. Factors that are predictive of viral titers 
will be included as covariates.
Patient -reported Outcomes 
The time to resolution of influenza symptoms will be the time of the first of 2 evaluations (over 
24 hours) in which all symptom scores for each of the 2 assessments are none or mild for the 
7primary  influenza symptoms as recorded in the Flu-iiQ™ (cough, sore throat, headache, nasal 
stuffiness, feverishness or chills, muscle or joint pain, and fatigue).
The FLU -PRO and Flu-iiQ™ domain scores will be presented descriptively  over time using 
descriptive statistics. A linear mixed model will be used to analyze composite symptom scores 
over time,per domain . For the Flu -iiQ™ a daily  score will be derived averaging observed scores 
before the anal ysis. Baseline subject characteristics will be included (in particular baseline score) 
in case these provide to be predictive of post-baseline scores. Mean differences between 
treatment arms will be derive d from this model using appropriate contrasts and will be presented 
including the associated 95% CI. For both measures, an AUC of composite symptom scores over 
a 7-and 14-day period per domain will be calculated and compared using a mixed model for 
repeated measurements .
Other PRO endpoints that will be analy zed are:
1.Time to return to usual activity  and usual health (Questions 5 and 9 of the additional items 
for the Flu -PRO). 
2.Time to significant re duction in influenza symptom severity .
3.Proportion of patients with a significant reduction (to mild or none for all influenza 
symptoms) at each assessment .
Other Outcomes
The length of overall hospital stay  will be calculated from the date of first study  drug inta keup to 
the date of discharge. Subjects still hospitalized at the end of the study  will be censored at the 
last contact. Data will be presented using Kaplan -Meier curves. For a comparison between 
treatment arms, the time to hospital discharge in days will be analyzed using an accelerated 
failure time model (if the data provide an acceptable model fit) or alternativel y a Cox 
proportional hazards model (in case the hazards are proportional). Additionally , the time to event 
data will be analyzed using the Gehan-Wilcoxon method. The time to resumption of normal 
daily  activities will be analy zed in an analogous fashion.
Resistance Analyses
The results of viral sequencing and phenoty ping will be evaluated by the sponsor virologist. 
Additional exploratory  characterization of the viral genoty pe and phenot ype may be performed 
and will be reported accordingl y.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
69
Approved , Date: 19 September 201611.7. Biomarker A nalyses
Statistical approaches to explore correlations between clinical outcome and blood biomarkers 
vary and depend on the different data ty pes of the applied technology platforms, as well as on the 
extent of observed differences between study  subjects. Analy ses may be conducted at the 
sponsor’s discretion and reported separatel y from this study .
The statistical approach for analyzing the exploratory  host DNA research may depend on the 
objective of the analyses (treatment response, side effects, metabolism) and possibly  relevant 
genes at the time of analy sis.Anal yses may be conducted, if deemed valuable, at the sponsor’s 
discretion and may  be reported separatel y from this study .
11.8. Data Monitoring Committee
An I DMC will be established to monitor data on an ongoing basis. The committee will meet 
periodicall y to review interim data. After the review, the IDMC will make recommendations 
regarding the continuation of the study .
An interim anal ysis may  be performed to support regulatory  activities.
The IDMC will consist of at least one medical expert in the relevant therapeutic area and at least 
one statistician. The IDMC responsibilities, authorities, and procedures will be documented in its 
charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with the treatment. An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investigational or non-investigational) produ ct. (Definition per International 
Conference on Harmonisation [I CH])
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
70
Approved , Date: 19 September 2016This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF (see Section 12.3.1 , All 
Adverse Events, for time of last AE recording).
Serious Adverse Event
AnSAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for 
Human Use is an y untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incap acity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definitio n above. 
These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship between the study  drug and the event (eg, death from anaph ylaxis), the event must 
be reported as a serious and unexpected suspected adverse reaction even if it is a component of 
the study  endpoint (eg, all -cause mortalit y). 
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AE is considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For JNJ-63623872 , since no adverse drug reaction s are 
currentl y identified in the Investigator's Brochure, all related SAEs are considered unexpected 
for reporting purposes. For oseltamivir with a marketing authorization, the expectedness of an 
AE will be determined by whether or not it is listed in the manufacturer’s prescribing 
information .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
71
Approved , Date: 19 September 2016Adverse Event Associated With the Use of the Drug
An AE is considered associated with the use of the drug if the attribution is possible, probable, or 
very likely  by the definitions listed in Section 12.1.2 .
12.1.2. Attribution Definitions
Not Related
An AEthat is not related to the use of the drug.
Doubtful
An AE for which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An AEthat might be due to the use of the drug. An alternative explanation, eg,concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AE that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed b y dechallenge). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An AE that is listed as a possible adverse reaction and cannot be reasonably  explained by an 
alternative explanation, eg, concomitant dr ug(s), concomitant disease(s). The relationship in time 
is very  suggestive (eg, it is confirmed by  dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the general categorical descriptors outlined 
in the WHO Toxicity  Grading Scale in Attachment 1.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Inadvertent or accidental exposure to a sponsor study  drug
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
72
Approved , Date: 19 September 2016Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation 
that meets the criteria of anSAE should be recorded on the Serious Adverse E vent page of 
the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated ICFis obtained until completion of the subject's last study -related 
procedure (which may include contact for follow -up of safet y). Serious AEs, including those 
spontaneously  reported to the investigator within 30days after the last dose of study  drug, must 
be reported electronically  via Electronic Data Capture (eDC) or via facsimile (fax) when 
applicable using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All events , including influenza complications that meet the definition of a nSAE will be reported 
as SAEs , regardless of whether they are protocol -specific assessments. Anticipated events will be 
recorded and reported as described in Attachment 2.
All AEs, regardless of seriousness, severit y, or presumed relationship to study  drug, must be 
recorded using medical terminology  in the source document sand the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respiratory  
infection"). Investigators must record in the eCRF their opinion concerning the relationship of 
the AE to study  therap y. All measures required for AE management must be recorded in the 
source document sand reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpe cted serious adverse reactions (SUSARs) . The investigator 
(or sponsor where required) must report SUSARs to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by the IEC/IRB .A SUSAR will be reported to regulatory  authorities 
unblinded. Participating investigators and IEC/IRB will receive a blinded SUSAR summary , 
unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
73
Approved , Date: 19 September 2016Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of t he blind
12.3.2. Serious A dverse Events
All SAEs occurring during thestudymust be reported to the appropriate sponsor contact person 
bystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event 
page of the eCRF, which must be completed and reviewed by a physician from the study  site, and 
transmitted to the sponsor within 24 hours. The initial and follow -up reports of an SAE should be 
transmitted electronically via eDC or via fax when applicable .
All SAEs that have not resolved by the end of the study , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by  a med icinal product will be reported as a n SAE . 
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the 
course of a subject's participation in a study  must be reported as anSAE , except hospitalizations 
for the following:
Hospitalizations not intended to treat an acute illness or AE (eg, social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underl ying condition for which the hospitalization was planned has not worsened ,will 
not be considered SAEs . Any AE that results in a prolongation of the originall y planned 
hospitalization is to be reported as a new SAE .
For convenience the investigator may choose to hospitalize the subject for the duration of 
the treatment period.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
74
Approved , Date: 19 September 2016Disease progression should not be recorded as an AE or SAE term; instead, signs and symptoms 
of clinical sequelae resulting from disease progression/lack of efficacy  will be reported if they 
fulfill the SAE definition ( see Section 12.1.1 , Adve rse Event Definitions and Classifications).
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by the study -site personnel within 24 hours of their knowledge of the event using 
the appropriate Pregnancy  Notification F orm. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered SAEs 
and must be reported electronicall y via eDC or via fax when applicable using the Serious 
Adverse Event Form. Any subject who becomes pregnant during the study  must discontinue 
further study  treatment .
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported by the study -site personnel within 24 hours of their 
knowledge of the event using the appropriate Pregnancy  Notification Form.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability ,or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protect ion of subjects, investigators, 
and the sponsor , and are mandated by regulatory  agencies worldwide. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with anSAE , the study -site personnel must report the PQC to the 
sponsor according to the SAE reporting timelines (see Section 12.3.2 , Serious Adverse Events). 
A sample of the suspected product should be maintained for further investigation if requested by 
the sponsor.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
75
Approved , Date: 19 September 201613.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
The JNJ-63623872 supplied for this study  is formulated as:300-mg tablets for oral 
administration, containing JNJ-63623872, microcry stalline cellulose, lactose monohy drate, 
croscarmellose sodium, povidone K30, sodium steary l fumarate, Opadr yII, white. 
A second formulation also containing the equivalent of 300 mg of JNJ-63623872 free base has 
been developed by the sponsor , which is also suitable for use in this study . The tablet contains
hypromellose, polysorbate 20, crospovidone, silica colloidal anhy drous, silicified 
microcry stalline cellulose, microc rystalline cellulose, pregelatinized starch, sodium steary l 
fumarate, Opadry  II yellow .
JNJ-63623872 formulations aremanufactured and provided under the responsibility  of the 
sponsor .The JNJ-6362 3872 formulation to be used in each different country  is determined by 
which one is approved by  each respective health authority .
Matching JNJ-63623872 placebo tablets for each of the active formulations are available and will 
be provided for subjec ts randomized to the placebo group.
Commerciall y available suppl ies of oseltamivir will be used, formulated as: 75-mg capsules or 
30-mg capsules for oral administration, containing oseltamivir phosphate, pregelatinized starch, 
talc, povidone K30, croscarme llose sodium, and sodium steary l fumarate.
14.2. Packaging
The study  drug (JNJ-63623872 or matching placebo tablets and oseltamivir capsules) will be 
provided on a blister card for each subject.
No study  drugs can be repacked without prior approval from the sponsor.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
Commercial oseltamivir capsules will be labeled with a study -specific label under the 
responsibility  of the sponsor.
No study  drugs can be relabele d without prior approval of the sponsor.
14.4. Preparation, Handling, and Storage 
All study  drug must be stored as specified on the label.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
76
Approved , Date: 19 September 2016Refer to the pharmacy  manual/ study  site investigational product manual for additional guidance on 
study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The study  drug administered to the subject must be 
documented on the drug accountability  form. In case subjects are discharged from the hospital 
during the treatment period, the dispensing of study  drug to the subject, and the return of study 
drug from the subject (if applicable), must be documented on the drug accountability  form. 
Subjects or their legall y acceptable representatives where applicable, must be instructed to return 
all original containers, whether empt y or containing study  drug. All study  drugswill be stored 
and disposed of according to the sponsor's instruction s. Study-site personnel must not combine 
contents of the study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug (and study  drug returned by the subject , where 
applicable) must be available for verification by the sponsor's study  site monitor during on-site 
monitoring visits. The return to the sponsor of unused study  drug (or used returned study  drug 
for destruction) will be documented on the Drug Return Form. When the study  site is an 
authorized destruction unit and study  drug supplies are destro yed on- site, this must also be 
documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel, or by a hospital/clinic pharmacist. Study  drug will be supplied only 
to subjects participating in the study . Returned study  drug must not be dispensed again, even to 
the same subject. Whenever a subject brings his or her study  drug to the study  site for pill count, 
this is not seen as a return of supplies. Study  drug may not be relabeled or reassigned for use by 
other subjects. The investigator agrees neither to dispense the study  drug from, nor store it at, 
any site other than the study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following supplies:
Investigator 'sBrochure of JNJ-63623872
Prescribing information for oseltamivir
Pharmacy  manual/ study  site investigational product manual
Laboratory  manual s (including procedures for collection of nasal swabs)
Contact information page(s)
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
77
Approved , Date: 19 September 2016ePRO device and user manual
IWRS Manual 
eDC Manual
Sample I CF
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential AEs of the study, and provide their consent voluntaril y will be enrolled.
The total blood volume to be collected is considered to be within the normal range allowed for this 
subject populat ion over this time frame.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and appli cable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Co mmittee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations) :
Final protocol and, i f applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
78
Approved , Date: 19 September 2016Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name o f the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approv al of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct ), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC /IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if ap plicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investiga tor's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change( s).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
79
Approved , Date: 19 September 2016At least once a year, the IEC/IRB will be asked to review and reapprove this study . The 
reapproval should be documented in writing (excluding the ones that are purel y administrative, 
with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
Each subject (or a legally acceptable representative) must give written consent according to local 
requirements after the nature of the study  has been fully  explained. The ICF(s) must be signed 
before performance of any study-related activity. The ICFthat areused must be approved by 
both the sponsor and by the reviewing IEC/I RB and be in a language that the subject can read 
and understand. The informed consent should be in accordance with principles that originated in 
the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory  
requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects or their legall y acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards ofthe study ,and any discomfort 
participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent to participate at any time. They  will be informed 
that choosing not to participate will not affect the care the subject will receive for the treatment 
of his or her disease. Subjects will be told that alternative treatments are available if they refuse 
to take part and that such refusal will not prejudice future treatment. Finally , they willbe told 
that the investigator will maintain a subject identification register for the purposes of long-term 
follow up if needed and that their records may be accessed by health authorities and authorized 
sponsor personnel without violating the confidentia lity of the subject, to the extent permitted by 
the applicable law(s) or regulations. By signing the ICF the subject or legall y acceptable 
representative is authorizing such access , including permission to obtain information about his or 
her survival status, and agrees to allow his or her study  physician to recontact the subject for the 
purpose of obtaining consent for additional safet y evaluations, if needed, and subsequent disease -
related treatments, or to obtain information a bout his or her survival stat us.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry  into the study , consent 
should be appropriatel y recorded by means of either thesubject's or his or her legally acceptable 
representative's personally  dated signature. After having obtained the consent, a copy of the ICF
must be given to the subject.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subject s enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
80
Approved , Date: 19 September 2016These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject (or his or her legally acceptable representative)
includes explicit consent for the processing of personal data and for the investigator /institution to 
allow direct access to his or her original medical records (source data/documents) for study -
related monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  biomarker and pharmacogenomic research is not conducted under standards
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigato rs, unless required by lawor local 
regulations . Privacy  and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand JNJ-63623872 and 
oseltamivir , to understand influenza A infection , to unders tand differential drug responders, and 
to develop tests/assays related to JNJ-63623872 and oseltamivir and influenza A infection. The 
research may  begin at any  time during the study  or the post -study  storage period.
Stored samples will be coded througho ut the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( see Section 10.3, Withdrawal From the Study  [Withdrawal From the Use of 
Samples in Future Research ]).
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly  addressed as a specific ethical 
consideration in Section 16.1, Study -Specific Design Consideratio ns.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
81
Approved , Date: 19 September 201617. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigato r. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amend ment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of thestudy , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representativ e (see Contact Information page[ s]provided separatel y). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the CRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member ofthe study -site personnel is a member of the IEC/IRB, documentation must be 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
82
Approved , Date: 19 September 2016obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study.
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated cl inical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applic able
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identification; study  
discussion and date of signed informed consent; dates of visits (including telephone follow -up 
calls, if applicable ); results of safety  and efficacy parameters as required by the protocol; record 
of all AEs and follow -up of AEs ; concomitant medication; drug receipt/dispensing/re turn 
records; study  drugadministration information ; and date of study  completion and reason for 
early discontinuation of study  drug or withdrawal from the study , if applicable.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
83
Approved , Date: 19 September 2016In addition, the author of an entry  in the source documents should be identifi able.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
The following data will be recorded directl y into the eCRF and will be considered source data: 
Race
History  of smoking
Blood pressure and pulse/heart rate 
Height and weight 
Details of ph ysical examination
The PRO assessments (Flu-iiQTM, Flu-PRO and additional daily  diary  items ) will be completed 
by subjects on an ePRO device. The results will be recorded directly  into the ePRO database and 
will be considered source data.
The minimum source documentation requirements for Section 4.1 ,Inclusion Criteria and Section 
4.2,Exclusion Criteria that specify  a need for documented medical history  are as follows:
Referral letter from treating ph ysician or
Complete history  ofmedical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject interview or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in electronic format.
Electronic Data Capture will be used for this study . The study  data will be transcribed by study-
sitepersonnel from the source documents into the eCRF, and transmitted in a secure manner to 
the sponsor within the timeframe agreed upon between the sponsor and the study  site. The 
electronic file will be considered to be the CRF.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study  must be recorded in eCRFs prepared by the sponsor. Data must be entered into CRFs in 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
84
Approved , Date: 19 September 2016English. Study site personnel must complete the eCRF as soon as possible after a subject visit, 
and the forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by the same individual who made the initial baseline determinations whenever 
possible. The investigator must verify that all data entries in the eCRFs are accurate and correct.
All eCRF entries, correction s, and alterations must be made by the investigator or other 
authorized study -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or study -site personnel must adjust the e CRF (if applicable) and complete the query .
If corrections to an eCRF are needed after the initial entry  into the eCRF, this can be done in 
3different way s:
Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool) .
Study site manager can generate a query  for resolution by  the study -site personnel.
Clinical data manager can generate a query  for resolution by  the study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by the sponsor, direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's database, and 
direct transmission of PRO data to the ePRO vendor database and then into the sponsor’s 
database . Written instructions will be provided for collection, handling, storage , and shipment of 
samples. 
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRFs for accuracy  and completeness during on-
site monitoring visits and after transmi ssion to the sponsor; any discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study  database 
they will be verified for accuracy  and consistency  with the data sources. 
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
85
Approved , Date: 19 September 2016Essential documents must beretained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuat ion of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will use a combina tion of monitoring techniques to monitor this study .
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRF with the hospital or clinic records (source 
documents) for completeness and accuracy , and perform source da ta verification to any source 
data captured on paper and entered in the system later. The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by 
the sponsor study -site contact. If electronic records are maintained at the study site, the method 
of verification must be discussed with the study -site personnel . 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the e CRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the study -site personnel . 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study  to provide feedback on the study  conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be availab le to provide an update on the progress 
of the study  at the site.
Central monitoring will take place for data identified by  the sponsor as requiring central review.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
86
Approved , Date: 19 September 201617.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last visit for the last subject participating in the 
study . The final data from the study site will be sent to the sponsor (or designee) after completion 
of the final subject visit at that study  site, in the time frame specified in the Clinical Trial 
Agreeme nt.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of th e intended termination.
Reasons for the early closure of astudy site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the CRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or it s designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should imme diately  notify  the sponsor if he or shehas
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding JNJ-63623872 or the 
sponsor's operations (eg,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by the sponsor to the investigator and 
not previously  published, and any  data, including exploratory  biomarker research data, generated 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
87
Approved , Date: 19 September 2016as a result of this study , are considered confidential and remain the sole property  of the sponsor. 
The investigator agrees to maintain this information in confidence and use this information only 
to accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of JNJ-63623872 , and thus may be
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all study  sites that participated in the study , laboratory  data from the 
selected laboratory that were transmitted to the sponsor ’s database, and PRO data from the ePRO 
vendor database that were transmitted to the sponsor ’s database . Recruitment performance or 
specific expertise related to the nature and the key assessment parameters of the study will be 
used to determine a coordinating investigator. Results of exploratory biomarker analy ses 
performed after the Clinical Study  Report has been issued will be reported in a separate report 
and will not require a revision of the Clinical Study  Report. Study  subject identifiers will not be 
used in publication o f results. Any  work created in connection with performance of the study  and 
contained in the data that can benefit from copyright protection (except anypublication by the 
investigator as provided for below) shall be the propert y of the sponsor as author and owner of 
copy right in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study , a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. For multicenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study  by not submitting for publication 
data derived from the individual study  site until the combined results from the completed study 
have been submitted for publication, within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
88
Approved , Date: 19 September 2016contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
89
Approved , Date: 19 September 2016REFERENCES
1. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin to 
creatinine ratio over albumin concentration. Diabetes Care 1999;22:307- 313.
2. Bazett HC. An anal ysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -380.
3. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta -analysis of 
randomised controlled trials. Lancet 2015;385:1729 –1737.
4. Dunning J, Bail lie JK, Cao B, Hayden FG. International Severe Acute Respiratory and Emerging Infection 
Consortium (ISARIC). Antiviral combinations for severe influenza. Lancet Infect Dis 2014;14(12):1259 -1270.
5. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
6. JNJ-63623872 Investigator’s Brochure Edition 4.0 (June 2015 ).
7. Lee N, Chan PKS, Hui DSC. Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized w ith 
Influenza. The Journal of Infectious Diseases. 2009;200:492 –500.
8. McNarry AF, Bateman DN. Simple bedside assessment of level of consciousness: comparison of two simple 
assessment sca les with the Glasgow Coma scale . Anaesthesia . 2004;59 : 34–37.
9. Modeling VX -787 Brief Communication, 12 August 2014. Population pharmacokinetic and exposure -response 
analysis for an anti -influenza compound (VX -787) to support phase 2b dose selection in community infected 
patients. Document No. VRT103100.
10. Sagie A, Larso n MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT interval 
for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70:797 -801.
11. Shrestha S, Swerdlow D, Borse R, et al. Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the 
United States (April 2009 –April 2010). Clin Infect Dis 2011; 52 (suppl 1): S75 -S82.
12. Smith GB, Prytherch DR, Meredith P, Schmid t PE, Featherstone PI . "The ability of the National Early 
Warning Score (NEWS) to discriminate patients at risk of e arly cardiac arrest, unanticipated intensive care unit 
admission, and death". Resuscitation . 2013; 84 : 465 –470.
13. South East Asia Infectious Disease Clinical Research Netw ork. Effect of double dose oseltamivir on clinical 
virological outcomes in children and adults admitted to hospital with severe influenza: double blind 
randomized controlled trial. BMJ. 2013;346:1 -16.
14. Tamiflu SmPC. UK: Roche Registration Ltd; 2012. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ -
_Product_Information/human/000402/WC500033106.pdf
15. Tamiflu USPI. Foster City, CA: Gilead Sciences, Inc; 2011. 
http://www.gene.com/download/pdf/tamiflu_prescribing.pdf
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
90
Approved , Date: 19 September 2016ATTACHMENT S
Attachm ent 1: WHO Toxicity Grading Scale for Determining the Severity of Adverse Events (Feb 2003 )
ABBREVIATIONS (used in the table):
ULN = Upper Limit of Normal
Rx= Therapy
FEV 1= forced expiratory volume in 1 secondLLN = Low er Limit of Normal
IV = Intravenous
ESTIMATING SEVERITY GRADE
For abnormalities NOT found elsewhere in the Toxicity Tables use the scale below to estimate grade of severity:
GRADE 1 Mild Transient or mild discomfort (<48 hours); no medical 
intervention/therapy required.
GRADE 2 Moderate Mild to moderate limitation in activity; some assistance may be needed; 
noor minimal medical intervention/ therapy required.
GRADE 3 Severe Marked limitation in activity; some assistance usually required; medical 
intervention/therapy required; hospitalizations possible.
GRADE 4 Potentially life-
threateningaExtreme limitation in activity; significant assistance required; 
significant medical intervention/therapy required; hospitalization or 
hospice care probable.
aRevised by the sponsor
COMMENTS REGARDING THE USE OF THESE TABLES
For parameters not included in the following Toxicity Tables, sites should refer to the “Guide For Estimating 
Severity Grade” located above.
Criteria are generally grouped by body system. Some protocols may have additional protocol -specific grading 
criteria, w hich will supersede the use of these tables for specified criteria.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
91
Approved , Date: 19 September 2016Item Grade 1 Grade 2 Grade 3 Grade 4
Hem atology
Hem oglobin 9.5-10.5 gm/dL 8.0-9.4 gm/dL 6.5-7.9 gm/dL <6.5 gm/dL
Absolute Neutrophil 
Count1,000-1,500/mm³ 750-999/mm ³ 500-749/mm ³ <500/mm ³
Platelets 75,000 -99,000/mm ³50,000 -74,999/mm ³ 20,000 -49,999/mm ³ <20,000/mm ³
Prothrombin Time 
(PT)≥1.01 to ≤1.25 x 
ULN>1.25 to ≤1.50 x 
ULN>1.50 to ≤3.00 x 
ULN>3.00 x ULN
Activated Partial 
Thromboplastin 
Time (aPTT)≥1.01 to ≤1.66 x 
ULN>1.66 to ≤2.33 x 
ULN>2.33 to ≤3.00 x 
ULN>3.00 x ULN
Fibrinogen ≥0.75 to ≤0.99 x 
LLN≥0.50 to <0.75 x LLN ≥0.25 to <0.50 x 
LLN<0.25 x LLN
Fibrin Split Product 20-40 mcg/mL 41-50 mcg/mL 51-60 mcg/mL >60 mcg/mL
Methemoglobin 5.0-9.9% 10.0-14.9% 15.0-19.9% >20.0%
Liver Enzymes
AST (SGOT) ≥1.25 to ≤2.50 x 
ULN>2.50 to ≤5.00 x 
ULN>5.00 to ≤10.00 x 
ULN>10.00 x ULN
ALT (SGPT) ≥1.25 to ≤2.50 x 
ULN>2.50 to ≤5.00 x 
ULN>5.00 to ≤10.00 x 
ULN>10.00 x ULN
Gamma -
glutamyltransferase≥1.25 to ≤2.50 x 
ULN>2.50 to ≤5.00 x 
ULN>5.00 to ≤10.00 x 
ULN>10.00 x ULN
Alkaline 
Phosphatase≥1.25 to ≤2.50 x 
ULN>2.50 to ≤5.00 x 
ULN>5.00 to ≤10.00 x 
ULN>10.00 x ULN
Amylase ≥1.1 to ≤1.5 x ULN >1.5 to ≤2.0 x ULN >2.0 to ≤5.0 x ULN >5.0 x ULN
Chemistries
Hyponatremia 130-135 mEq/L 123-129 mEq/L 116-122 mEq/L <116 mEq/L or 
mental status 
changes or 
seizures
Hypernatremia 146-150 mEq/L 151-157 mEq/L 158-165 mEq/L >165 mEq/L or 
mental status 
changes or 
seizures
Hypokalemia 3.0-3.4 mEq/L 2.5-2.9 mEq/L 2.0-2.4 mEq/L or 
intensive 
replacement Rx 
required or 
hospitalization 
required<2.0 mEq/L or 
paresis or ileus or 
life-threatening 
arrhythmia
Hyperkalemia 5.6-6.0 mEq/L 6.1-6.5 mEq/L 6.6-7.0 mEq/L >7.0 mEq/L or 
life-threatening 
arrhythmia
Hypoglycemia 55-64 mg/dL 40-54 mg/dL 30-39 mg/dL <30 mg/dL or 
mental status 
changes or coma
Hyperglycemia 
(note if fasting )116-160 mg/dL 161-250 mg/dL 251-500 mg/dL >500 mg/dL or 
ketoacidosis or 
seizures
Hypocalcemia 
(corrected for 
albumin)8.4-7.8 mg/dL 7.7-7.0 mg/dL 6.9-6.1 mg/dL <6.1 mg/dL or 
life-threatening 
arrhythmia or 
tetany
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
92
Approved , Date: 19 September 2016Item Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia 
(corrected for 
albumin)10.6-11.5 mg/dL 11.6-12.5 mg/dL 12.6-13.5 mg/dL >13.5 mg/dL or 
life-threatening 
arrhythmia
Hypomagnesemia 1.4-1.2 mEq/L 1.1-0.9 mEq/L 0.8-0.6 mEq/L <0.6 mEq/L or 
life-threatening 
arrhythmia
Hypophosphatemia 2.0-2.4 mg/dL 1.5-1.9 mg/dL or 
replacement Rx 
required1.0-1.4 mg/dL 
intensive Rx or 
hospitalization 
required<1.0 mg/dL or 
life-threatening 
arrhythmia
Hyperbilirubinemia ≥1.1 to ≤1.5 x ULN >1.5 to ≤2.5 x ULN >2.5 to ≤5.0 x ULN >5.0 x ULN
BUN ≥1.25 to ≤2.50 x 
ULN>2.50 to ≤5.00 x 
ULN>5.00 to ≤10.00 x 
ULN>10.00 x ULN
Creatinine ≥1.1 to ≤1.5 x ULN >1.5 to ≤3.0 x ULN >3.0 to ≤6.0 x ULN >6.0 x ULN or 
required dialysis
Urinalysis
Proteinuria 1+ or <0.3% or 
<3g/L or 
200 mg – 1gm 
loss/day2-3+ or 0.3 -1.0% or 
3-10 g/L or 
1-2 gm loss/day4+ or >1.0% or 
>10g/L or 
2-3.5 gm loss/daynephrotic 
syndrome or 
>3.5 gm loss/day
Hem aturia microscopic only gross, no clots gross + clots obstructive or 
required 
transfusion
Cardiac Dysfunction
Cardiac Rhythm - asymptomatic, 
transient signs, no 
Rx requiredrecurrent/persistent; 
no Rx requiredrequires Rx
Hypertension transient inc. 
>20mm; no Rxrecurrent, chronic, 
>20 mm, Rx 
requiredrequires acute Rx; no 
hospitalizationrequires 
hospitalization
Hypotension transient orthostatic 
hypotension, no Rxsymptoms 
correctable w ith oral 
fluids Rxrequires IV fluids; no 
hospitalization 
requiredrequires 
hospitalization
Pericarditis minimal effusion mild/moderate 
asymptomatic 
effusion, no Rxsymptomatic 
effusion; pain; ECG 
changestamponade; 
pericardiocentesis 
or surgery 
required
Hem orrhage, Blood 
Lossmicroscopic/occult mild, no transfusion gross blood loss; 
1-2units transfusedmassive blood 
loss; >3 units 
transfused
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
93
Approved , Date: 19 September 2016Item Grade 1 Grade 2 Grade 3 Grade 4
Respiratory
Cough transient; no Rx treatment associated 
cough ;local Rxuncontrolled -
Bronchospasm, 
Acutetransient; no Rx 
<80-70% FEV 1
(orpeak flow )requires Rx 
norm alizes with 
bronchodilator; 
FEV 150-70% (or 
peak flow)no normalization 
with bronchodilator; 
FEV 125-50% (or 
peak flow 
retractions)cyanosis: FEV 1
<25% (or peak 
flow) or intubated
Gastrointestinal
Stomatitis mild discomfort; no 
limits on activitysome limits on 
eating/drinkingeating/talking very 
limitedrequires IV fluids
Nausea mild discomfort; 
maintains 
reasonable intakemoderate discomfort; 
intake decreased 
significantly; some 
activity limitedsevere discomfort; 
no significant intake; 
activities limitedminimal fluid 
intake
Vom iting transient emesis occasional/moderate 
vomitingorthostatic 
hypotension or IV 
fluids requiredhypotensive 
shock or 
hospitalization 
required for IV 
fluid therapy
Constipation mild moderate severe distensions 
w/vomiting
Diarrhea transient 3 -4 loose 
stools/day5-7 loose stools/day orthostatic 
hypotension or 
>7loose stools/day 
or required IV fluidshypotensive 
shock or 
hospitalization 
for IV fluid 
therapy required
Neuro & Neuromuscular
Neuro -Cerebellar slight incoordination 
dysdiadochokinesisintention tremor, 
dysmetria, slurred 
speech; nystagmuslocomotor ataxia incapacitated
Mood mild anxiety or 
depressionmoderate anxiety or 
depression and Rx
requiredsevere anxiety or 
depression or mania; 
needs assistanceacute psychosis; 
incapacitated, 
requires 
hospitalization
Neuro Control 
(ADL = activities of 
daily living)mild difficulty 
concentrating; no 
Rx; mild 
confusion/agitation; 
ADL unaffectedmoderate 
confusion/agitation 
some limitation of 
ADL; minimal Rxsevere 
confusion/agitation 
needs assistance for 
ADL; Rxrequiredtoxic psychosis; 
hospitalization
Muscle Strength subjective weakness 
no objective 
symptoms/ signsmild objective 
signs/symptoms no 
decrease in functionobjective w eakness 
function limitedparalysis
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
94
Approved , Date: 19 September 2016Item Grade 1 Grade 2 Grade 3 Grade 4
Other Param eters
Fever: oral, 
>12hours37.7-38.5 °C or 
100.0 -101.5 °F38.6-39.5 °C or 
101.6 -102.9 °F39.6-40.5 °C or 
103-105 °F>40°C or 
>105 °F
Headache mild, no Rx transient, moderate; 
Rx requiredsevere; responds to 
initial narcotic 
therapyintractable; 
required repeated 
narcotic therapy
Fatigue no decrease in ADL norm al activity 
decreased 25 -50%norm al activity 
decreased >50% 
can’t w orkunable to care for 
self
Allergic Reaction pruritus without 
rashlocalized urticaria generalized urticaria; 
angioedemaanaphylaxis
Local Reaction tenderness or 
erythemainduration <10 cm or 
phlebi tis or 
inflammationinduration >10 cm or 
ulcerationnecrosis
Mucocutaneous Erythema ; pruritus diffuse, 
maculopapular rash, 
dry desquamationvesiculation, moist 
desquamation ,or
ulcerationexfoliative 
dermatitis, 
mucous 
membrane 
involvement, or 
erythema 
multiforme or 
suspected 
Stevens -Johnson 
ornecrosis 
requiring surgery
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
95
Approved , Date: 19 September 2016Attachm ent 2: Anticipated Events
An anticipated event is an AE (serious or non-serious) that commonly occurs as a consequence of the 
underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be considered anticipated events: 
Bacterial pneumonia
Bronchitis
Sinus infections
Ear infections
Worsening of asthm a, asthma attack
COPD exacerbation
Complications of sickle cell disease , sickle cell crisis
Complications of diabetes mellitus, diabetic ketoacidosis
Acute respiratory distress syndrome (ARDS)
Reporting of Anticipated Events
These events will be captured on the CRF and in the database, and will be reported to the sponsor as
described in Section 12.3.1, All Adverse Events . Any event that meets SAE criteria will be reported to the 
sponsor within the appropriate timeline as described in Section 12.3.2 , Serious Adverse Events. These 
anticipated events are exempt from expedited reporting as individual single cases to Health Authorities. 
However if based on an aggregate review, it is determ ined that an anticipated event is possibly related to 
study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
In this study, the IDMC will perform the role of an Anticipated Event Review Committee (ARC) and will 
conduct reviews of pre -specified anticipated events at an aggregate level. The IDMC will provide the 
recommendation to the Sponsor Committee as to whether there is a reasonable possibility that an 
anticipated event is related to the study dru g.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan ( ASMP).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
96
Approved , Date: 19 September 2016Attachm ent 3:Influenza I ntensity and Impact Questionnaire (Flu -iiQTM)
This attachment provides a representative example of the Flu -iiQTMquestionnaire that will be used in this study.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
97
Approved , Date: 19 September 2016
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
98
Approved , Date: 19 September 2016Attachm ent 4: Additional Daily Diary Items to Flu -iiQTM
This attachment provides a representative example of the additional daily diary items to Flu -iiQTMthat will be used 
in this study.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
99
Approved , Date: 19 September 2016Attachm ent 5:Flu-PRO Questionnaire
This attachment provides a representative example of the Flu -PRO questionnaire that will be used in this study.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
100
Approved , Date: 19 September 2016
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
101
Approved , Date: 19 September 2016Attachm ent 6:Additional Daily Diary Items to Flu-PRO
This attachment provides a representative example of the additional daily diary items to Flu -PRO that will be used 
in this study.
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
102
Approved , Date: 19 September 2016
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
103
Approved , Date: 19 September 2016Attachm ent 7: Cardiovascular Safety -Abnorm alities 
ECG
All important abnormalities from the ECG readings will be listed.
Abnormality CodeECG parameter
HR PR QRS QT corrected
Abnormalities on actual values
Abnorm ally low < 45 bpm < 110 ms - -
Abnorm ally high 120 bpm > 220 ms 120 ms -
Borderline prolonged QT (males) - - - 450 ms < QTc 480 ms
Borderline prolonged QT (females) - - - 470 ms < QTc 480ms
Prolonged QT - - - 480 ms < QTc <500 ms
Pathologically prolonged QT - - - QTc > 500 ms
Abnormalities on changes from baseline ( ∆QTc)
Normal QTc change - - - ∆QTc < 30 ms
Borderline QTc change - - - 30 ms <∆QTc <60 ms
Abnorm ally high QTc change - - - ∆QTc > 60 ms
For absolute QTc parameters the categories are defined based on the ICH E14 Guidance 13F13F13F13F13Fa
Vital Signsb
The following abnormalities will be defined for vital signs:
Abnormality CodeVital Signs parameter
Pulse DBP SBP
Abnormalities on actual values
Abnorm ally low < 45 bpm 50 mmHg 90 mmHg
Grade 1 or mild - > 90 mmHg -< 100 mmHg > 140 mmHg -< 160 mmHg
Grade 2 or moderate - 100 mmHg -< 110 mmHg 160 mmHg - <180 mmHg
Grade 3 or severe - 110 mmHg 180 mmHg
Abnorm ally high 120 bpm - -
                                                
aThe clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 
CHMP/ICH/2/04, May 2005.
bThe classification of AEs related to hypotension and hypertension will be done according to the WHO grading 
scale ( see also Attachment 1 ).
[STUDY_ID_REMOVED]
JNJ-63623872
Clinical Protocol Amendment 3 63623872FLZ2002
104
Approved , Date: 19 September 2016INVESTIGA TOR AGREEME NT
I have read this document and agree that it contains all necessary details for carrying out this study. I will 
conduct the study as outlined herein and will complete the study within the time designated.
I will provide copies of the document and all pertinent information to all individuals responsible to me 
who assist in the conduct of this study. I will discuss this material with them to ensure that they are fully 
informed regarding the study drug, the conduct of the study, and the obligations of confidentiality.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: Date:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: Date:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): Lorant Leopold
Institution: Janssen Research & Development
Signature: [electronic signature appended at the end of the protocol] Date:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by the investigator to the sponsor, and a protocol amendment will not be required.
LAST P AGE
[STUDY_ID_REMOVED]